{"gene":"BTK","run_date":"2026-04-28T17:12:38","timeline":{"discoveries":[{"year":1993,"finding":"BTK was identified as the gene defective in X-linked agammaglobulinemia (XLA); it encodes a cytoplasmic protein-tyrosine kinase expressed in B cells and belonging to the Src family of proto-oncogenes.","method":"Positional cloning, mutation analysis in XLA families, expression studies","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — original positional cloning with mutation validation, foundational discovery replicated independently","pmids":["8380905","8425221"],"is_preprint":false},{"year":1994,"finding":"The pleckstrin homology (PH) domain of BTK directly interacts with protein kinase C (PKC) isoforms (alpha, beta I, beta II, epsilon, zeta) in mast cells; PKC phosphorylates BTK and down-regulates its enzymatic activity.","method":"GST-fusion pulldown with mast cell lysates, co-immunoprecipitation from intact cells, in vitro kinase assay, PKC depletion/inhibition experiments","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro binding, in vivo co-IP, and functional kinase assays with multiple PKC isoforms","pmids":["7522330"],"is_preprint":false},{"year":1994,"finding":"The PH domain of BTK binds the beta-gamma dimer of heterotrimeric G proteins in vitro and in vivo; a conserved tryptophan in subdomain 6 of the PH domain is critical for this interaction, linking BTK to G-protein-coupled signaling.","method":"In vitro binding assay, in vivo competition assay, site-directed mutagenesis of PH domain tryptophan","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro and in vivo binding with mutagenesis identifying critical residue","pmids":["7972043"],"is_preprint":false},{"year":1994,"finding":"BTK mRNA and protein are expressed broadly in hematopoietic lineages (B cells, monocytes, mast cells, myeloid cells) but are selectively down-regulated in T lymphocytes and plasma cells.","method":"Northern blotting, immunoprecipitation, Western blotting, PCR-based analysis across diverse cell lines and primary cells","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods across many cell types, replicated pattern","pmids":["8283037"],"is_preprint":false},{"year":1995,"finding":"Genetic ablation of BTK's PH or kinase domain in mice causes reduced conventional B cell numbers, severe B1 cell deficiency, serum IgM/IgG3 deficiency, and defective responses to thymus-independent type II antigens, recapitulating the Xid phenotype and proving BTK is required for B lymphocyte development and activation.","method":"Targeted gene disruption in ES cells (deletion of PH or kinase domain), RAG2-deficient blastocyst complementation, germline introduction; in vitro and in vivo immunological assays","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 1-2 — rigorous genetic loss-of-function with multiple phenotypic readouts, complementation experiments","pmids":["7552994"],"is_preprint":false},{"year":1996,"finding":"BTK is activated by SRC family kinases through transphosphorylation at tyrosine 551 (Y551) in the kinase activation loop; this leads to BTK autophosphorylation at a second site and membrane association of the activated kinase. The same two sites are phosphorylated upon BCR cross-linking.","method":"In vitro kinase assay, phosphopeptide mapping, site-directed mutagenesis, cell-based BCR crosslinking with phosphorylation analysis","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 — in vitro biochemical reconstitution with mutagenesis and in vivo receptor stimulation, replicated","pmids":["8629002"],"is_preprint":false},{"year":1996,"finding":"The major BTK autophosphorylation site is Y223 within the SH3 domain; mutation of Y223 to F blocks autophosphorylation and potentiates the transforming activity of the gain-of-function Btk* (E41K) mutant, indicating that autophosphorylation at Y223 negatively regulates SH3-mediated signaling.","method":"Phosphopeptide mapping, site-directed mutagenesis (Y223F), fibroblast transformation assay, co-expression with Src kinase","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis with functional transformation readout, mechanistic mapping of autophosphorylation site","pmids":["8630736"],"is_preprint":false},{"year":1998,"finding":"BTK promotes radiation-induced apoptosis (pro-apoptotic via down-regulation of STAT3 anti-apoptotic activity) but inhibits Fas-activated apoptosis by associating with the death receptor Fas and impairing its interaction with FADD, thereby preventing assembly of the death-inducing signaling complex (DISC).","method":"Co-immunoprecipitation (BTK-Fas interaction), functional apoptosis assays, STAT3 activity measurements","journal":"Biochemical pharmacology","confidence":"Medium","confidence_rationale":"Tier 2-3 — co-IP with functional apoptosis assays, single lab, mechanistic follow-up","pmids":["9751072"],"is_preprint":false},{"year":2000,"finding":"BCAP (B cell adaptor for PI3K) is tyrosine-phosphorylated by both Syk and BTK downstream of BCR engagement; phosphorylated BCAP binds the p85 subunit of PI3K and recruits PI3K to lipid rafts (GEMs), mediating PIP3 generation and Akt activation.","method":"BCAP gene disruption in DT40 cells, co-immunoprecipitation, PIP3 measurement, Akt phosphorylation assay, subcellular fractionation","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 1-2 — genetic KO with multiple orthogonal biochemical readouts, clear pathway placement of BTK","pmids":["11163197"],"is_preprint":false},{"year":2001,"finding":"BLNK (B cell linker protein) mediates Syk-dependent BTK activation: BLNK allows Syk to phosphorylate BTK at Y551 through a BLNK–BTK SH2 domain interaction, thereby enhancing BTK activity. BCR-induced BTK phosphorylation and activation are significantly reduced in BLNK-deficient B cells.","method":"Reconstitution cell system with co-expression experiments, BCR-induced phosphorylation assays in BLNK-deficient and Syk-deficient B cells, SH2-domain interaction analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 — reconstitution in cells plus genetic deficiency models, mechanistic identification of scaffold role of BLNK","pmids":["11226282"],"is_preprint":false},{"year":2002,"finding":"Endogenous BTK and Akt interact with each other in B cells, and this interaction is inducible by H2O2 stimulation; BTK and Akt co-localize in the perinuclear region and membrane ruffles, and BTK is involved in PI3K-dependent Akt phosphorylation following oxidative stress.","method":"Co-immunoprecipitation from DT40 and Nalm6 B cells, confocal co-localization in COS-7 cells, PI3K inhibition experiments, phosphorylation assays","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2-3 — reciprocal co-IP plus co-localization in multiple cell lines, single lab","pmids":["12054657"],"is_preprint":false},{"year":2003,"finding":"BTK binds directly to the Toll/IL-1 receptor (TIR) domains of TLR4, TLR6, TLR8, and TLR9, as well as to the TLR adaptor proteins MyD88, Mal, and IRAK-1 (but not TRAF-6); BTK is activated (tyrosine-phosphorylated) by LPS/TLR4 stimulation and is required for TLR4-mediated NF-κB activation.","method":"Co-immunoprecipitation, dominant-negative BTK expression, NF-κB reporter assay, kinase activity assay, BTK-specific inhibitor (LFM-A13) experiments","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — multiple interaction assays with functional NF-κB readout, genetic and pharmacologic inhibition, replicated across cell lines","pmids":["12724322"],"is_preprint":false},{"year":2006,"finding":"BTK phosphorylates the TLR adaptor protein Mal, which then interacts with SOCS-1, leading to Mal polyubiquitination and degradation. This negative-feedback mechanism limits TLR2/TLR4-dependent NF-κB activation.","method":"Co-immunoprecipitation, phosphorylation assays, ubiquitination assays, genetic KO and overexpression of SOCS-1, NF-κB reporter assays","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal biochemical and genetic approaches establishing direct substrate relationship and functional consequence","pmids":["16415872"],"is_preprint":false},{"year":2009,"finding":"Activation loop phosphorylation at Y551 by Src-family kinase Lyn is required for BTK kinase domain activity: the isolated kinase domain is largely inactive without Y551 phosphorylation; in vitro phosphorylation restores full activity comparable to full-length BTK. BTK also requires a second Mg2+ ion for activity.","method":"In vitro kinase reconstitution using Lyn-mediated phosphorylation of isolated BTK kinase domain, mass spectrometry phosphorylation mapping, kinetic analysis, divalent metal dependence studies","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with detailed kinetic analysis and mass spectrometry, rigorous mechanistic study","pmids":["19206206"],"is_preprint":false},{"year":2012,"finding":"BTK is required for NK cell activation via the TLR3 pathway; Btk-/- murine NK cells show decreased IFN-γ, perforin, and granzyme-B expression and reduced cytotoxicity; BTK promotes TLR3-triggered NK cell activation mainly by activating the NF-κB pathway. BTK-deficient (XLA) human NK cells also show reduced TLR3-triggered activation.","method":"Btk knockout mouse studies, adoptive transfer experiments, in vivo BTK inhibitor administration, XLA patient NK cell functional assays, cytokine and surface marker measurements","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — genetic KO with multiple functional readouts, human XLA patient validation, in vivo model","pmids":["22589540"],"is_preprint":false},{"year":2013,"finding":"BTK and Vav1 are recruited to phagocytic cups during Dectin-1-mediated phagocytosis of Candida albicans in macrophages; BTK co-localizes with PI(3,4,5)P3 and F-actin at the cup; BTK contributes to DAG synthesis and subsequent PKCε recruitment at the phagocytic cup; BTK- or Vav1-deficient macrophages show impaired phagocytosis and mice are more susceptible to systemic C. albicans infection.","method":"Co-immunoprecipitation (Dectin-1 interactors), fluorescence microscopy/live imaging, selective BTK inhibitor, BTK- and Vav1-deficient mouse macrophages (peritoneal and bone-marrow-derived), in vivo infection model","journal":"PLoS pathogens","confidence":"High","confidence_rationale":"Tier 2 — direct localization with functional consequence, genetic KO validation in vitro and in vivo, pharmacological confirmation","pmids":["23825946"],"is_preprint":false},{"year":2014,"finding":"Ibrutinib (PCI-32765) irreversibly inhibits BTK by covalently modifying Cys481; resistance in CLL arises from a C481S mutation at this site (making BTK only reversibly inhibited) or from gain-of-function mutations in downstream PLCγ2 (R665W, L845F) that produce autonomous BCR activity.","method":"Whole-exome sequencing at baseline and relapse, functional analysis of C481S mutation, Ion Torrent targeted sequencing","journal":"The New England journal of medicine","confidence":"High","confidence_rationale":"Tier 1-2 — functional characterization of resistance mutations with genetic sequencing and in vitro validation, widely replicated","pmids":["24869598"],"is_preprint":false},{"year":2015,"finding":"BTK is an essential component of the NLRP3 inflammasome: BTK physically interacts with both ASC and NLRP3; pharmacological or genetic inhibition of BTK severely impairs NLRP3 inflammasome activation, caspase-1 cleavage, and IL-1β secretion. In a mouse brain ischemia model, ibrutinib suppresses infarct volume and neurological damage by inhibiting inflammasome-mediated IL-1β maturation in infiltrating macrophages and neutrophils.","method":"Co-immunoprecipitation (BTK-ASC and BTK-NLRP3), pharmacological BTK inhibition (ibrutinib), genetic BTK-deficient mice, mouse brain ischemia/reperfusion model, caspase-1 and IL-1β assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1-2 — direct protein-protein interactions demonstrated by co-IP, genetic and pharmacologic loss-of-function with clear functional readouts, in vivo model","pmids":["26059659"],"is_preprint":false},{"year":2015,"finding":"BTK drives macrophage polarization toward a TH2 phenotype in pancreatic ductal adenocarcinoma (PDAC) via a B cell–macrophage cross-talk involving FcRγ+ tumor-associated macrophages and PI3Kγ-dependent BTK activation; BTK inhibition with ibrutinib reprograms macrophages toward TH1 and restores CD8+ T-cell cytotoxicity against PDAC.","method":"BTK inhibitor (ibrutinib) in PDAC mouse models, PI3Kγ inhibition, macrophage phenotyping, T-cell functional assays, tumor growth measurements","journal":"Cancer discovery","confidence":"High","confidence_rationale":"Tier 2 — genetic and pharmacologic epistasis establishing BTK's role in immune cross-talk with defined cellular phenotype","pmids":["26715645"],"is_preprint":false},{"year":2015,"finding":"Autoinhibited BTK adopts a compact inactive conformation (analogous to c-Src and c-Abl) stabilized by the PH-TH module together with SH2 and SH3 domains; inositol hexakisphosphate (IP6) activates BTK by inducing transient PH-TH dimerization that promotes transphosphorylation of kinase domains. PIP3-containing membranes also activate BTK by a related mechanism.","method":"X-ray crystallography of BTK domains, biochemical activity assays, IP6 binding experiments, mutagenesis of PH-TH interface","journal":"eLife","confidence":"High","confidence_rationale":"Tier 1 — crystal structures combined with biochemical validation and mutagenesis in a single rigorous study","pmids":["25699547"],"is_preprint":false},{"year":2016,"finding":"BTK phosphorylates p53 in response to DNA damage, creating a positive feedback loop that increases p53 protein levels and enhances transactivation of p53 target genes; BTK induction leads to enhanced p53-dependent senescence and apoptosis, while BTK inhibition reduces both responses.","method":"BTK inhibition and overexpression in cell lines, DNA damage assays, p53 phosphorylation analysis, senescence assays, apoptosis assays","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2-3 — functional assays with phosphorylation readout, single lab, limited mechanistic dissection of direct vs. indirect phosphorylation","pmids":["27630139"],"is_preprint":false},{"year":2018,"finding":"The BTK C481S mutation drives ibrutinib resistance via reactivation of BTK–PLCγ2–ERK1/2 signaling; ibrutinib-treated BTKCys481Ser cells release pro-survival cytokines IL-6 and IL-10 through an ERK1/2-dependent mechanism, and these cytokines protect BTK-wild-type MYD88-mutated cells from ibrutinib via a paracrine mechanism.","method":"Engineered BTKCys481Ser-expressing cell lines, ERK1/2 inhibitor experiments, Transwell co-culture system, IL-6/IL-10 blocking antibodies, serum cytokine analysis in WM patients","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (engineered cells, inhibitors, antibody blocking, patient samples) in single study establishing paracrine mechanism","pmids":["29496671"],"is_preprint":false},{"year":2019,"finding":"Noncovalent BTK inhibitors reveal that the gatekeeper residue T474 and kinase domain residues (L512M, E513G, F517L, L547P) are critical for BTK activity; co-occurrence of gatekeeper and kinase domain mutations in cis produces 10-15-fold gain of BTK kinase activity and de novo transforming potential, disrupting an intramolecular autoinhibitory mechanism.","method":"Systematic BTK mutagenesis screen, in vitro transformation assays, in vivo xenograft models, computational structural analysis","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 1-2 — systematic mutagenesis with in vitro and in vivo functional validation and structural modeling","pmids":["31217352"],"is_preprint":false},{"year":2021,"finding":"BTK is a required signaling node downstream of Fc receptors in microglia: MOG autoantibody-induced microglial proliferation is amplified in BtkE41K constitutively-active knock-in mice and blunted by a CNS-penetrant BTK inhibitor; this establishes BTK as mediating FcR-driven microglial responses in the CNS.","method":"In vivo MOG antibody injection model, FcγR knockout mice, BtkE41K knock-in mice, CNS-penetrant BTK inhibitor treatment, microglial proliferation and gene expression assays","journal":"Brain","confidence":"High","confidence_rationale":"Tier 2 — gain-of-function and loss-of-function genetic models with pharmacologic confirmation and in vivo phenotypic readouts","pmids":["34145876"],"is_preprint":false},{"year":2021,"finding":"In ABC-DLBCL, primary resistance to BTK inhibitor ibrutinib is epigenetic: the transcription factor TCF4 drives a phenotypic shift in which RAC2 substitutes for BTK to activate PLCγ2 and sustain NF-κB signaling; elevated RAC2–PLCγ2 interaction was also observed in CLL cells from patients with persistent disease on BTK inhibitors.","method":"Ibrutinib resistance modeling in DLBCL cells, transcriptomic and epigenetic profiling, RNAi/genetic perturbation, biochemical interaction assays, patient CLL cell analysis","journal":"Blood cancer discovery","confidence":"Medium","confidence_rationale":"Tier 2 — multi-method study establishing bypass mechanism, patient validation, but single lab","pmids":["34778802"],"is_preprint":false},{"year":2021,"finding":"MARCKS is a BTK substrate in CLL cells: BCR stimulation induces MARCKS phosphorylation that is reduced by BTK inhibitors; MARCKS sequesters PIP2 and affects BCR clustering; genetic loss of MARCKS increases AKT signaling and migratory capacity of CLL cells.","method":"Phosphoproteomic analysis under ibrutinib treatment, MARCKS genetic knockdown, AKT signaling assays, migration assays, clinical correlation with acalabrutinib treatment","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 — phosphoproteomics plus genetic KD with functional readouts, patient correlation","pmids":["33735912"],"is_preprint":false},{"year":2022,"finding":"Kinase-dead BTK mutants C481F and C481Y maintain BCR signaling by physically recruiting hematopoietic cell kinase (HCK): Src family kinases phosphorylate mutant BTK at Y551, which engages HCK's SH2 domain, disrupts HCK's autoinhibition, and activates HCK to phosphorylate PLCγ2, sustaining NF-κB signaling and clonogenic proliferation independently of BTK kinase activity.","method":"In vitro kinase assays confirming kinase-dead status, structural modeling, co-immunoprecipitation (BTK-HCK), phosphorylation assays, BCR signaling pathway analysis, clonogenic assay","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro kinase assays, co-IP, structural modeling, and functional assays identifying scaffold mechanism","pmids":["35639855"],"is_preprint":false},{"year":2023,"finding":"Pirtobrutinib (a noncovalent BTK inhibitor) stabilizes BTK in a closed, inactive conformation through an extensive interaction network in the ATP-binding region that does not contact C481; it prevents Y551 phosphorylation in the activation loop and inhibits both wild-type and C481-mutant BTK with similar potencies.","method":"Differential scanning fluorimetry, enzymatic inhibition assays, cell-based phosphorylation assays, in vivo xenograft models, kinome selectivity profiling","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 — biophysical and biochemical characterization with structural and functional validation across multiple assay formats","pmids":["36796019"],"is_preprint":false},{"year":2024,"finding":"Some drug-resistant BTK mutants (including kinase-impaired forms) sustain BCR signaling through novel protein-protein interactions that scaffold downstream effectors independently of BTK kinase activity; NX-2127, a BTK/IKZF1/3 degrader, can bind and proteasomally degrade each mutant BTK proteoform, achieving >80% BTK degradation in CLL patients and potent BCR signaling blockade.","method":"Characterization of acquired resistance mutations, in vitro enzymatic activity assays, protein-protein interaction studies, PROTAC-mediated degradation assays, clinical treatment with NX-2127","journal":"Science","confidence":"High","confidence_rationale":"Tier 1-2 — multiple biochemical assays plus clinical proof-of-concept, identifying scaffold function of mutant BTK","pmids":["38301010"],"is_preprint":false},{"year":2024,"finding":"BTK drives antifungal immunity in neutrophils: upon fungal exposure, BTK is activated in human neutrophils via TLR2, Dectin-1, and FcγR signaling, triggering the oxidative burst; BTK inhibition selectively blocks Aspergillus hyphal damage and primary granule release by abrogating NADPH oxidase subunit p40phox and GTPase RAC2 activation; neutrophil-specific Btk deletion in mice enhances aspergillosis susceptibility.","method":"Human neutrophil activation assays, BTK inhibitor treatment, XLA patient neutrophil studies, neutrophil-specific Btk conditional KO mice, p40phox and RAC2 activation assays, in vivo aspergillosis model, GM-CSF rescue experiments","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — genetic conditional KO with multiple functional readouts, human patient validation, in vivo infection model","pmids":["38696257"],"is_preprint":false}],"current_model":"BTK is a cytoplasmic Tec-family tyrosine kinase that is activated downstream of multiple receptors (BCR, TLRs, FcRs, Dectin-1, G-protein-coupled receptors) through a two-step phosphorylation mechanism: Src-family kinases (e.g., Lyn) transphosphorylate the activation loop at Y551, followed by BTK autophosphorylation at Y223 in the SH3 domain; membrane recruitment via PH domain binding to PIP3 (or IP6-induced PH-TH dimerization) is essential for activation; activated BTK phosphorylates substrates including PLCγ2, BCAP, Mal, p53, and MARCKS to regulate Ca2+ flux, NF-κB, PI3K-Akt, and NLRP3 inflammasome pathways, controlling B cell development, survival, and innate immune effector functions in macrophages, NK cells, neutrophils, and microglia; drug-resistant BTK mutations can render the kinase catalytically inactive while preserving oncogenic scaffold functions through recruitment of alternative kinases (HCK) or novel protein-protein interactions, which are overcome by PROTAC-mediated BTK degradation."},"narrative":{"teleology":[{"year":1993,"claim":"Identification of BTK as the gene mutated in X-linked agammaglobulinemia established that a cytoplasmic tyrosine kinase is essential for human B cell development, framing the central biological question of how it transduces receptor signals.","evidence":"Positional cloning and mutation analysis in XLA families","pmids":["8380905","8425221"],"confidence":"High","gaps":["Substrates and downstream signaling pathways unknown","Activation mechanism uncharacterized","Expression in non-B lineages not yet established"]},{"year":1994,"claim":"Demonstration that the BTK PH domain binds Gβγ subunits and PKC isoforms, together with broad hematopoietic expression profiling, revealed BTK as a multi-input signaling node extending beyond the BCR.","evidence":"GST-fusion pulldowns, co-immunoprecipitation, in vitro kinase assays, mutagenesis of PH domain tryptophan, Northern/Western blotting across cell lineages","pmids":["7522330","7972043","8283037"],"confidence":"High","gaps":["PH domain lipid-binding specificity not yet resolved","Physiological relevance of G-protein coupling in B cells unclear","PKC phosphorylation sites on BTK not mapped"]},{"year":1995,"claim":"Genetic ablation of BTK PH or kinase domains in mice recapitulated the Xid phenotype—reduced B cells, B1 cell loss, IgM/IgG3 deficiency—providing definitive genetic proof that BTK kinase activity and membrane recruitment are both required for B lymphocyte development.","evidence":"Targeted gene disruption in ES cells with RAG2-deficient blastocyst complementation and immunological assays","pmids":["7552994"],"confidence":"High","gaps":["Specific signaling events downstream of BTK in developing B cells undefined","Role of BTK in non-B hematopoietic cells not yet tested in vivo"]},{"year":1996,"claim":"Mapping the two-step activation mechanism—Y551 transphosphorylation by Src-family kinases followed by Y223 autophosphorylation in the SH3 domain—resolved how BTK is switched on and revealed that Y223 phosphorylation serves a negative regulatory role by modulating SH3-mediated interactions.","evidence":"In vitro kinase assays, phosphopeptide mapping, site-directed mutagenesis (Y551, Y223F), BCR crosslinking, fibroblast transformation assays","pmids":["8629002","8630736"],"confidence":"High","gaps":["Identity of the scaffold bridging Src-family kinases to BTK unknown","Structural basis of autoinhibition unresolved","In vivo significance of Y223 phosphorylation not tested"]},{"year":2000,"claim":"Discovery that BTK (together with Syk) phosphorylates the adaptor BCAP to recruit PI3K and generate PIP3 placed BTK upstream of the PI3K-Akt axis within the BCR signaling cascade, and identification of BLNK as the scaffold enabling Syk-dependent BTK activation resolved how BTK is activated in a receptor-proximal complex.","evidence":"BCAP and BLNK gene disruption in DT40 cells, PIP3 measurement, Akt phosphorylation, co-immunoprecipitation, SH2 domain interaction analysis","pmids":["11163197","11226282"],"confidence":"High","gaps":["Full spectrum of BTK substrates unknown","Quantitative contribution of BTK versus Syk to BCAP phosphorylation not determined"]},{"year":2003,"claim":"Demonstration that BTK directly binds TIR domains of multiple TLRs and the adaptors MyD88, Mal, and IRAK-1, and is required for TLR4-mediated NF-κB activation, established BTK as an innate immune signaling kinase beyond its BCR role.","evidence":"Co-immunoprecipitation, dominant-negative BTK, NF-κB reporter assays, kinase activity assays, pharmacological BTK inhibition","pmids":["12724322"],"confidence":"High","gaps":["Structural basis of BTK-TIR interaction unknown","Role of BTK in TLR signaling in primary innate immune cells not fully dissected"]},{"year":2006,"claim":"Identification of Mal as a direct BTK substrate whose phosphorylation triggers SOCS-1-mediated ubiquitination and degradation revealed a negative-feedback loop limiting TLR2/TLR4 signaling, showing BTK can both activate and terminate innate immune pathways.","evidence":"Phosphorylation assays, ubiquitination assays, SOCS-1 genetic manipulation, NF-κB reporter assays","pmids":["16415872"],"confidence":"High","gaps":["Sites of BTK-mediated Mal phosphorylation not fully mapped","Whether this feedback operates equivalently across all TLR-expressing cell types unknown"]},{"year":2012,"claim":"Establishing that BTK is required for TLR3-driven NK cell activation extended BTK's functional domain beyond B cells and macrophages into NK cell innate immunity.","evidence":"Btk knockout mice, adoptive transfer, in vivo BTK inhibitor, XLA patient NK cell assays","pmids":["22589540"],"confidence":"High","gaps":["Direct BTK substrates in NK cells not identified","Whether BTK regulates other NK receptor pathways unknown"]},{"year":2013,"claim":"Recruitment of BTK to Dectin-1-dependent phagocytic cups in macrophages, where it colocalizes with PIP3 and drives DAG synthesis for PKCε recruitment, established BTK as an effector of antifungal phagocytic immunity.","evidence":"Live imaging, co-immunoprecipitation, BTK inhibitor, BTK-deficient macrophages, in vivo Candida infection model","pmids":["23825946"],"confidence":"High","gaps":["Direct substrates at the phagocytic cup not identified","Relative contribution of BTK versus Syk to Dectin-1 signaling unclear"]},{"year":2014,"claim":"Discovery that ibrutinib resistance arises from the BTK C481S gatekeeper mutation or gain-of-function PLCγ2 mutations defined the first clinical resistance mechanisms and highlighted the pharmacological vulnerability of the covalent bond to Cys481.","evidence":"Whole-exome sequencing of CLL patients at baseline and relapse, functional analysis of C481S","pmids":["24869598"],"confidence":"High","gaps":["Whether kinase-dead Cys481 mutants retain signaling function not yet explored","Resistance mechanisms beyond Cys481 and PLCγ2 undefined"]},{"year":2015,"claim":"Structural resolution of BTK autoinhibition—a compact conformation stabilized by PH-TH, SH2, and SH3 modules, relieved by IP6-induced PH-TH dimerization—provided the first atomic-level explanation of how membrane recruitment triggers kinase activation, complementing the biochemical activation model.","evidence":"X-ray crystallography, IP6 binding experiments, mutagenesis of PH-TH dimerization interface, in vitro kinase assays","pmids":["25699547"],"confidence":"High","gaps":["Full-length BTK structure not solved","Dynamics of PH-TH dimerization on native membranes not captured"]},{"year":2015,"claim":"Demonstration that BTK physically interacts with ASC and NLRP3 and is required for inflammasome activation, caspase-1 cleavage, and IL-1β maturation broadened BTK's role to sterile inflammation and ischemic brain injury.","evidence":"Co-immunoprecipitation of BTK-ASC and BTK-NLRP3, Btk-deficient mice, ibrutinib treatment, mouse brain ischemia model","pmids":["26059659"],"confidence":"High","gaps":["Whether BTK phosphorylates NLRP3 or ASC directly is unknown","Mechanism of BTK-NLRP3 interaction not structurally resolved"]},{"year":2019,"claim":"Systematic mutagenesis revealing that co-occurring gatekeeper (T474) and kinase-domain mutations produce a 10–15-fold gain in kinase activity with de novo transforming potential uncovered a mechanism by which autoinhibition can be catastrophically disrupted.","evidence":"Systematic BTK mutagenesis screen, in vitro transformation assays, in vivo xenografts, computational structural analysis","pmids":["31217352"],"confidence":"High","gaps":["Frequency of these compound mutations in patients not determined","Structural basis of synergistic autoinhibition loss not fully resolved"]},{"year":2022,"claim":"Discovery that kinase-dead BTK C481F/C481Y mutants sustain BCR signaling by recruiting HCK via Y551-SH2 interactions revealed a kinase-independent scaffold function, fundamentally redefining the drug target from enzymatic activity to protein presence.","evidence":"In vitro kinase assays confirming kinase-dead status, co-immunoprecipitation of BTK-HCK, phosphorylation and clonogenic assays","pmids":["35639855"],"confidence":"High","gaps":["Full repertoire of kinases recruited by scaffold BTK unknown","Whether scaffold function operates in non-B cell contexts unexplored"]},{"year":2024,"claim":"PROTAC-mediated degradation of mutant BTK proteoforms (NX-2127) achieved >80% BTK depletion in CLL patients and blocked BCR signaling irrespective of kinase activity, providing clinical proof-of-concept that degradation overcomes scaffold-mediated resistance; separately, neutrophil-specific Btk deletion established BTK as essential for NADPH oxidase-dependent antifungal defense via p40phox and RAC2 activation.","evidence":"PROTAC degradation assays and clinical trial data; conditional Btk KO mice, human XLA neutrophils, in vivo aspergillosis model","pmids":["38301010","38696257"],"confidence":"High","gaps":["Long-term clinical efficacy of BTK degraders unknown","Mechanism by which BTK activates p40phox and RAC2 not fully dissected","Impact of BTK degradation on NLRP3 inflammasome versus inhibition not compared"]},{"year":null,"claim":"A full-length BTK structure in its native membrane context, the complete substrate repertoire in each innate immune cell type, and the structural basis of BTK's scaffold interactions with HCK and NLRP3 remain unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No full-length BTK structure on membranes","Complete substrate inventory in macrophages, neutrophils, and microglia lacking","Structural mechanism of kinase-independent scaffold signaling unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[5,6,8,12,13,20,25,26]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[26,28]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[2,19]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,5,10]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[5,15,19]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,4,11,12,14,15,17,18,23,29]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[5,6,8,9,11,16,21,26]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[16,21,24,26,28]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[7,20]}],"complexes":["NLRP3 inflammasome"],"partners":["PLCG2","BLNK","HCK","LYN","NLRP3","PYCARD","MYD88","TIRAP"],"other_free_text":[]},"mechanistic_narrative":"BTK is a cytoplasmic Tec-family tyrosine kinase that serves as a central signaling hub in B cell development, innate immunity, and inflammatory responses across multiple hematopoietic lineages. BTK is activated downstream of the B cell receptor (BCR), Toll-like receptors, Fc receptors, and Dectin-1 through a two-step mechanism: Src-family kinase (Lyn)-mediated transphosphorylation at Y551 in the activation loop—scaffolded by the adaptor BLNK—followed by autophosphorylation at Y223 in the SH3 domain, with membrane recruitment via PH domain binding to PIP3 or IP6-induced PH-TH dimerization required for activation [PMID:8629002, PMID:8630736, PMID:11226282, PMID:25699547]. Activated BTK phosphorylates PLCγ2, BCAP, the TLR adaptor Mal, and MARCKS to regulate calcium flux, NF-κB signaling, PI3K-Akt activation, and NLRP3 inflammasome assembly, thereby controlling B cell maturation, macrophage polarization, NK cell cytotoxicity, microglial Fc receptor responses, and neutrophil oxidative burst during antifungal defense [PMID:11163197, PMID:16415872, PMID:26059659, PMID:22589540, PMID:34145876, PMID:38696257]. Loss-of-function mutations in BTK cause X-linked agammaglobulinemia (XLA), while drug-resistant kinase-dead BTK mutants retain oncogenic scaffold functions by recruiting alternative kinases such as HCK, a vulnerability overcome by PROTAC-mediated BTK degradation [PMID:8380905, PMID:35639855, PMID:38301010]."},"prefetch_data":{"uniprot":{"accession":"Q06187","full_name":"Tyrosine-protein kinase BTK","aliases":["Agammaglobulinemia tyrosine kinase","ATK","B-cell progenitor kinase","BPK","Bruton tyrosine kinase"],"length_aa":659,"mass_kda":76.3,"function":"Non-receptor tyrosine kinase indispensable for B lymphocyte development, differentiation and signaling (PubMed:19290921). Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately leads to B-cell activation (PubMed:19290921). After BCR engagement and activation at the plasma membrane, phosphorylates PLCG2 at several sites, igniting the downstream signaling pathway through calcium mobilization, followed by activation of the protein kinase C (PKC) family members (PubMed:11606584). PLCG2 phosphorylation is performed in close cooperation with the adapter protein B-cell linker protein BLNK (PubMed:11606584). BTK acts as a platform to bring together a diverse array of signaling proteins and is implicated in cytokine receptor signaling pathways (PubMed:16517732, PubMed:17932028). Plays an important role in the function of immune cells of innate as well as adaptive immunity, as a component of the Toll-like receptors (TLR) pathway (PubMed:16517732). The TLR pathway acts as a primary surveillance system for the detection of pathogens and are crucial to the activation of host defense (PubMed:16517732). Especially, is a critical molecule in regulating TLR9 activation in splenic B-cells (PubMed:16517732, PubMed:17932028). Within the TLR pathway, induces tyrosine phosphorylation of TIRAP which leads to TIRAP degradation (PubMed:16415872). BTK also plays a critical role in transcription regulation (PubMed:19290921). Induces the activity of NF-kappa-B, which is involved in regulating the expression of hundreds of genes (PubMed:19290921). BTK is involved on the signaling pathway linking TLR8 and TLR9 to NF-kappa-B (PubMed:19290921). Acts as an activator of NLRP3 inflammasome assembly by mediating phosphorylation of NLRP3 (PubMed:34554188). Transiently phosphorylates transcription factor GTF2I on tyrosine residues in response to BCR (PubMed:9012831). GTF2I then translocates to the nucleus to bind regulatory enhancer elements to modulate gene expression (PubMed:9012831). ARID3A and NFAT are other transcriptional target of BTK (PubMed:16738337). BTK is required for the formation of functional ARID3A DNA-binding complexes (PubMed:16738337). There is however no evidence that BTK itself binds directly to DNA (PubMed:16738337). BTK has a dual role in the regulation of apoptosis (PubMed:9751072). Plays a role in STING1-mediated induction of type I interferon (IFN) response by phosphorylating DDX41 (PubMed:25704810)","subcellular_location":"Cytoplasm; Cell membrane; Nucleus; Membrane raft","url":"https://www.uniprot.org/uniprotkb/Q06187/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BTK","classification":"Not Classified","n_dependent_lines":9,"n_total_lines":1208,"dependency_fraction":0.0074503311258278145},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/BTK","total_profiled":1310},"omim":[{"mim_id":"621356","title":"SH3 AND CYSTEINE-RICH DOMAINS 2; STAC2","url":"https://www.omim.org/entry/621356"},{"mim_id":"615214","title":"AGAMMAGLOBULINEMIA 7, AUTOSOMAL RECESSIVE; AGM7","url":"https://www.omim.org/entry/615214"},{"mim_id":"608232","title":"LEUKEMIA, CHRONIC MYELOID; CML","url":"https://www.omim.org/entry/608232"},{"mim_id":"606457","title":"INHIBITOR OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE; IBTK","url":"https://www.omim.org/entry/606457"},{"mim_id":"605988","title":"DNA CROSS-LINK REPAIR PROTEIN 1C; DCLRE1C","url":"https://www.omim.org/entry/605988"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Cytosol","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"bone marrow","ntpm":24.2},{"tissue":"lymphoid tissue","ntpm":62.7}],"url":"https://www.proteinatlas.org/search/BTK"},"hgnc":{"alias_symbol":["ATK","XLA","PSCTK1"],"prev_symbol":["AGMX1","IMD1"]},"alphafold":{"accession":"Q06187","domains":[{"cath_id":"2.30.29.30","chopping":"5-166","consensus_level":"high","plddt":86.5294,"start":5,"end":166},{"cath_id":"2.30.30.40","chopping":"217-270","consensus_level":"high","plddt":88.7531,"start":217,"end":270},{"cath_id":"3.30.505.10","chopping":"281-375","consensus_level":"high","plddt":86.8325,"start":281,"end":375},{"cath_id":"3.30.200.20","chopping":"398-474","consensus_level":"high","plddt":88.1227,"start":398,"end":474},{"cath_id":"1.10.510.10","chopping":"479-657","consensus_level":"high","plddt":92.5988,"start":479,"end":657}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q06187","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q06187-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q06187-F1-predicted_aligned_error_v6.png","plddt_mean":84.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BTK","jax_strain_url":"https://www.jax.org/strain/search?query=BTK"},"sequence":{"accession":"Q06187","fasta_url":"https://rest.uniprot.org/uniprotkb/Q06187.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q06187/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q06187"}},"corpus_meta":[{"pmid":"23782157","id":"PMC_23782157","title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.","date":"2013","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23782157","citation_count":1345,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7552994","id":"PMC_7552994","title":"Defective B cell development and function in Btk-deficient mice.","date":"1995","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/7552994","citation_count":600,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19290921","id":"PMC_19290921","title":"Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain.","date":"2009","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/19290921","citation_count":398,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31075187","id":"PMC_31075187","title":"Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.","date":"2019","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31075187","citation_count":246,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33777941","id":"PMC_33777941","title":"Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/33777941","citation_count":204,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26957112","id":"PMC_26957112","title":"Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor.","date":"2016","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26957112","citation_count":190,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23958373","id":"PMC_23958373","title":"Ibrutinib and novel BTK inhibitors in clinical development.","date":"2013","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23958373","citation_count":187,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37407001","id":"PMC_37407001","title":"Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.","date":"2023","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37407001","citation_count":173,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9695187","id":"PMC_9695187","title":"Btk function in B cell development and response.","date":"1998","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9695187","citation_count":154,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30093506","id":"PMC_30093506","title":"The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.","date":"2018","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/30093506","citation_count":140,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29631132","id":"PMC_29631132","title":"The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.","date":"2018","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29631132","citation_count":139,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24603851","id":"PMC_24603851","title":"miR-7 inhibits glioblastoma growth by simultaneously interfering with the PI3K/ATK and Raf/MEK/ERK pathways.","date":"2014","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24603851","citation_count":118,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35417637","id":"PMC_35417637","title":"Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia.","date":"2022","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35417637","citation_count":112,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11226282","id":"PMC_11226282","title":"BLNK mediates Syk-dependent Btk activation.","date":"2001","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11226282","citation_count":112,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38301010","id":"PMC_38301010","title":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.","date":"2024","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/38301010","citation_count":111,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26341110","id":"PMC_26341110","title":"BTK Signaling in B Cell Differentiation and Autoimmunity.","date":"2016","source":"Current topics in microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26341110","citation_count":110,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36796019","id":"PMC_36796019","title":"Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor.","date":"2023","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/36796019","citation_count":108,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34803999","id":"PMC_34803999","title":"Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34803999","citation_count":106,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28641100","id":"PMC_28641100","title":"Bruton's tyrosine kinase (BTK) as a promising target in solid tumors.","date":"2017","source":"Cancer treatment reviews","url":"https://pubmed.ncbi.nlm.nih.gov/28641100","citation_count":105,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8520028","id":"PMC_8520028","title":"The Btk subfamily of cytoplasmic tyrosine kinases: structure, regulation and function.","date":"1995","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8520028","citation_count":95,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25699547","id":"PMC_25699547","title":"Autoinhibition of Bruton's tyrosine kinase (Btk) and activation by soluble inositol hexakisphosphate.","date":"2015","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/25699547","citation_count":89,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24357428","id":"PMC_24357428","title":"Bruton's tyrosine kinase (BTK) inhibitors in clinical trials.","date":"2014","source":"Current hematologic malignancy reports","url":"https://pubmed.ncbi.nlm.nih.gov/24357428","citation_count":83,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35901282","id":"PMC_35901282","title":"Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance.","date":"2022","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/35901282","citation_count":79,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29496671","id":"PMC_29496671","title":"BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism.","date":"2018","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/29496671","citation_count":77,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34276674","id":"PMC_34276674","title":"BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34276674","citation_count":76,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23825946","id":"PMC_23825946","title":"Bruton's Tyrosine Kinase (BTK) and Vav1 contribute to Dectin1-dependent phagocytosis of Candida albicans in macrophages.","date":"2013","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/23825946","citation_count":74,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9751072","id":"PMC_9751072","title":"Bruton's tyrosine kinase (BTK) as a dual-function regulator of apoptosis.","date":"1998","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/9751072","citation_count":69,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36287227","id":"PMC_36287227","title":"Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.","date":"2023","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/36287227","citation_count":69,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38478390","id":"PMC_38478390","title":"BTK inhibitors in CLL: second-generation drugs and beyond.","date":"2024","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/38478390","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22589540","id":"PMC_22589540","title":"Tyrosine kinase Btk is required for NK cell activation.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22589540","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24556163","id":"PMC_24556163","title":"Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma.","date":"2014","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/24556163","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8885720","id":"PMC_8885720","title":"X-linked agammaglobulinemia (XLA): a genetic tyrosine kinase (Btk) disease.","date":"1996","source":"BioEssays : news and reviews in molecular, cellular and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/8885720","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28901789","id":"PMC_28901789","title":"Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.","date":"2017","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/28901789","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9287186","id":"PMC_9287186","title":"Role of Btk in B cell development and signaling.","date":"1997","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9287186","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38141832","id":"PMC_38141832","title":"BTK signaling-a crucial link in the pathophysiology of chronic spontaneous urticaria.","date":"2023","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38141832","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34778802","id":"PMC_34778802","title":"Overcoming Acquired Epigenetic Resistance to BTK Inhibitors.","date":"2021","source":"Blood cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/34778802","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33740548","id":"PMC_33740548","title":"Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.","date":"2021","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33740548","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34349760","id":"PMC_34349760","title":"Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34349760","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30888232","id":"PMC_30888232","title":"Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018).","date":"2019","source":"Expert opinion on therapeutic patents","url":"https://pubmed.ncbi.nlm.nih.gov/30888232","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7633420","id":"PMC_7633420","title":"Identification of Btk mutations in 20 unrelated patients with X-linked agammaglobulinaemia (XLA).","date":"1995","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7633420","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31949019","id":"PMC_31949019","title":"Low-dose Btk inhibitors selectively block platelet activation by CLEC-2.","date":"2021","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/31949019","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34145876","id":"PMC_34145876","title":"MOG autoantibodies trigger a tightly-controlled FcR and BTK-driven microglia proliferative response.","date":"2021","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/34145876","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27669440","id":"PMC_27669440","title":"From identification of the BTK kinase to effective management of leukemia.","date":"2016","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/27669440","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27630139","id":"PMC_27630139","title":"BTK Modulates p53 Activity to Enhance Apoptotic and Senescent Responses.","date":"2016","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/27630139","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32401033","id":"PMC_32401033","title":"A Fast and Clean BTK Inhibitor.","date":"2020","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32401033","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10075013","id":"PMC_10075013","title":"Signalling of Bruton's tyrosine kinase, Btk.","date":"1999","source":"Scandinavian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10075013","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34299259","id":"PMC_34299259","title":"Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34299259","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34885993","id":"PMC_34885993","title":"The Development of BTK Inhibitors: A Five-Year Update.","date":"2021","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/34885993","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30706214","id":"PMC_30706214","title":"Development of BTK inhibitors for the treatment of B-cell malignancies.","date":"2019","source":"Archives of pharmacal research","url":"https://pubmed.ncbi.nlm.nih.gov/30706214","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21635151","id":"PMC_21635151","title":"Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man.","date":"2011","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/21635151","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11102316","id":"PMC_11102316","title":"Bruton tyrosine kinase (BTK) in X-linked agammaglobulinemia (XLA).","date":"2000","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/11102316","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26165234","id":"PMC_26165234","title":"Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia.","date":"2015","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/26165234","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35639855","id":"PMC_35639855","title":"Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK.","date":"2022","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/35639855","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25105368","id":"PMC_25105368","title":"Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model.","date":"2014","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/25105368","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39025681","id":"PMC_39025681","title":"BTK inhibitors: past, present, and future.","date":"2024","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39025681","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34509879","id":"PMC_34509879","title":"Discovery of novel BTK PROTACs for B-Cell lymphomas.","date":"2021","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34509879","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34651869","id":"PMC_34651869","title":"The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma.","date":"2021","source":"Hematological oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34651869","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11213806","id":"PMC_11213806","title":"The cellular phenotype conditions Btk for cell survival or apoptosis signaling.","date":"2000","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/11213806","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36712232","id":"PMC_36712232","title":"Discovery of a potent BTK and IKZF1/3 triple degrader through reversible covalent BTK PROTAC development.","date":"2022","source":"Current research in chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/36712232","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34091303","id":"PMC_34091303","title":"Novel irreversible covalent BTK inhibitors discovered using DNA-encoded chemistry.","date":"2021","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34091303","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33718366","id":"PMC_33718366","title":"Targeting the NLRP3 Inflammasome via BTK.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/33718366","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12405164","id":"PMC_12405164","title":"XLA patients with BTK splice-site mutations produce low levels of wild-type BTK transcripts.","date":"2002","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12405164","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34479103","id":"PMC_34479103","title":"Progress in the development of small molecular inhibitors of the Bruton's tyrosine kinase (BTK) as a promising cancer therapy.","date":"2021","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34479103","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34596095","id":"PMC_34596095","title":"COVID-19 and X-linked agammaglobulinemia (XLA) - insights from a monogenic antibody deficiency.","date":"2021","source":"Current opinion in allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34596095","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36402930","id":"PMC_36402930","title":"Managing Waldenström's macroglobulinemia with BTK inhibitors.","date":"2022","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/36402930","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38696257","id":"PMC_38696257","title":"BTK drives neutrophil activation for sterilizing antifungal immunity.","date":"2024","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/38696257","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20634142","id":"PMC_20634142","title":"TLR signaling and effector functions are intact in XLA neutrophils.","date":"2010","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/20634142","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12054657","id":"PMC_12054657","title":"Interaction of Btk and Akt in B cell signaling.","date":"2002","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12054657","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38656399","id":"PMC_38656399","title":"BTK inhibition limits microglia-perpetuated CNS inflammation and promotes myelin repair.","date":"2024","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/38656399","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35437106","id":"PMC_35437106","title":"Cardiotoxicity of BTK inhibitors: ibrutinib and beyond.","date":"2022","source":"Expert review of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/35437106","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31397086","id":"PMC_31397086","title":"Effects of BTK signalling in pathogenic microorganism infections.","date":"2019","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31397086","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39048721","id":"PMC_39048721","title":"Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia.","date":"2024","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/39048721","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37119666","id":"PMC_37119666","title":"Discovery of novel BTK PROTACs with improved metabolic stability via linker rigidification strategy.","date":"2023","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37119666","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31217352","id":"PMC_31217352","title":"Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity.","date":"2019","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/31217352","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19161832","id":"PMC_19161832","title":"Phylogeny of Tec family kinases identification of a premetazoan origin of Btk, Bmx, Itk, Tec, Txk, and the Btk regulator SH3BP5.","date":"2008","source":"Advances in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19161832","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38542207","id":"PMC_38542207","title":"Targeting BTK in B Cell Malignancies: From Mode of Action to Resistance Mechanisms.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38542207","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31819516","id":"PMC_31819516","title":"Long Non-Coding RNA HOTAIR Modulates KLF12 to Regulate Gastric Cancer Progression via PI3K/ATK Signaling Pathway by Sponging miR-618.","date":"2019","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31819516","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32640487","id":"PMC_32640487","title":"BTK/ITK dual inhibitors: Modulating immunopathology and lymphopenia for COVID-19 therapy.","date":"2020","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/32640487","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30956999","id":"PMC_30956999","title":"Bruton's tyrosine kinase (Btk) inhibitor tirabrutinib suppresses osteoclastic bone resorption.","date":"2019","source":"Bone reports","url":"https://pubmed.ncbi.nlm.nih.gov/30956999","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38137005","id":"PMC_38137005","title":"Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL).","date":"2023","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/38137005","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35330376","id":"PMC_35330376","title":"Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors.","date":"2022","source":"Journal of personalized medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35330376","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30509085","id":"PMC_30509085","title":"TCF19 enhances cell proliferation in hepatocellular carcinoma by activating the ATK/FOXO1 signaling pathway.","date":"2018","source":"Neoplasma","url":"https://pubmed.ncbi.nlm.nih.gov/30509085","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38965189","id":"PMC_38965189","title":"Comparative CNS Pharmacology of the Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib Versus Other BTK Inhibitor Candidates for Treating Multiple Sclerosis.","date":"2024","source":"Drugs in R&D","url":"https://pubmed.ncbi.nlm.nih.gov/38965189","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33419778","id":"PMC_33419778","title":"Follicular Lymphoma-associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation.","date":"2021","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/33419778","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38211337","id":"PMC_38211337","title":"How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia.","date":"2024","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/38211337","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35157769","id":"PMC_35157769","title":"BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL.","date":"2022","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/35157769","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33735912","id":"PMC_33735912","title":"MARCKS affects cell motility and response to BTK inhibitors in CLL.","date":"2021","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/33735912","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33937249","id":"PMC_33937249","title":"Targeting Solid Tumors With BTK Inhibitors.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/33937249","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38597202","id":"PMC_38597202","title":"Bruton's tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): current progress and latest advances.","date":"2024","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/38597202","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15180538","id":"PMC_15180538","title":"Therapeutic potential of inhibiting Bruton's tyrosine kinase, (BTK).","date":"2004","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/15180538","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32614787","id":"PMC_32614787","title":"ROR2 knockdown suppresses breast cancer growth through PI3K/ATK signaling.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/32614787","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36377973","id":"PMC_36377973","title":"BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma.","date":"2022","source":"Future oncology (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/36377973","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7865793","id":"PMC_7865793","title":"Inflorescence-specific expression of AtK-1, a novel Arabidopsis thaliana homologue of shaggy/glycogen synthase kinase-3.","date":"1995","source":"Plant molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7865793","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31843459","id":"PMC_31843459","title":"Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors.","date":"2019","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31843459","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33613931","id":"PMC_33613931","title":"Current and novel BTK inhibitors in Waldenström's macroglobulinemia.","date":"2021","source":"Therapeutic advances in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/33613931","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9159207","id":"PMC_9159207","title":"BTK, the tyrosine kinase affected in X-linked agammaglobulinemia.","date":"1997","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/9159207","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19206206","id":"PMC_19206206","title":"Activation loop phosphorylation modulates Bruton's tyrosine kinase (Btk) kinase domain activity.","date":"2009","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19206206","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38578606","id":"PMC_38578606","title":"New Means and Challenges in the Targeting of BTK.","date":"2024","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/38578606","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34727961","id":"PMC_34727961","title":"Huiyang Shengji decoction promotes wound healing in diabetic mice by activating the EGFR/PI3K/ATK pathway.","date":"2021","source":"Chinese medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34727961","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32494164","id":"PMC_32494164","title":"Bruton's Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)-Suppressed Migration and Invasion of Prostate Cancer.","date":"2020","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32494164","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25636800","id":"PMC_25636800","title":"Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation.","date":"2015","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/25636800","citation_count":1601,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8380905","id":"PMC_8380905","title":"The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases.","date":"1993","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8380905","citation_count":1242,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8425221","id":"PMC_8425221","title":"Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia.","date":"1993","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8425221","citation_count":1134,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24869598","id":"PMC_24869598","title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.","date":"2014","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24869598","citation_count":1055,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15772651","id":"PMC_15772651","title":"The DNA sequence of the human X chromosome.","date":"2005","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/15772651","citation_count":816,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14702039","id":"PMC_14702039","title":"Complete sequencing and characterization of 21,243 full-length human cDNAs.","date":"2003","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14702039","citation_count":754,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22939624","id":"PMC_22939624","title":"Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22939624","citation_count":708,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21422473","id":"PMC_21422473","title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21422473","citation_count":662,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7925280","id":"PMC_7925280","title":"Prolactin induces phosphorylation of Tyr694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription.","date":"1994","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/7925280","citation_count":542,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8125298","id":"PMC_8125298","title":"Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides.","date":"1994","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/8125298","citation_count":492,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25910212","id":"PMC_25910212","title":"Widespread macromolecular interaction perturbations in human genetic disorders.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25910212","citation_count":454,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16415872","id":"PMC_16415872","title":"Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation.","date":"2006","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16415872","citation_count":444,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24658273","id":"PMC_24658273","title":"Targeting Bruton's tyrosine kinase in B cell malignancies.","date":"2014","source":"Nature reviews. Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24658273","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26715645","id":"PMC_26715645","title":"Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer.","date":"2015","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/26715645","citation_count":410,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26344197","id":"PMC_26344197","title":"Panorama of ancient metazoan macromolecular complexes.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26344197","citation_count":407,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8629002","id":"PMC_8629002","title":"Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases.","date":"1996","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/8629002","citation_count":391,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26059659","id":"PMC_26059659","title":"Bruton's tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury.","date":"2015","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/26059659","citation_count":365,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7522330","id":"PMC_7522330","title":"The pleckstrin homology domain of Bruton tyrosine kinase interacts with protein kinase C.","date":"1994","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7522330","citation_count":312,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29851337","id":"PMC_29851337","title":"Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.","date":"2018","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29851337","citation_count":302,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8630736","id":"PMC_8630736","title":"Regulation of Btk function by a major autophosphorylation site within the SH3 domain.","date":"1996","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/8630736","citation_count":261,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12724322","id":"PMC_12724322","title":"Bruton's tyrosine kinase is a Toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor kappaB activation by Toll-like receptor 4.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12724322","citation_count":250,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8283037","id":"PMC_8283037","title":"Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells.","date":"1994","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8283037","citation_count":241,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7972043","id":"PMC_7972043","title":"Binding of beta gamma subunits of heterotrimeric G proteins to the PH domain of Bruton tyrosine kinase.","date":"1994","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7972043","citation_count":240,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11163197","id":"PMC_11163197","title":"BCAP: the tyrosine kinase substrate that connects B cell receptor to phosphoinositide 3-kinase activation.","date":"2000","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/11163197","citation_count":225,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":44039,"output_tokens":5186,"usd":0.104954},"stage2":{"model":"claude-opus-4-6","input_tokens":8725,"output_tokens":3827,"usd":0.20895},"total_usd":0.689342,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":56312,"output_tokens":7430,"usd":0.140193},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":11426,"output_tokens":3988,"usd":0.235245}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"BLNK (SLP-65) mediates Syk-dependent BTK activation: BLNK scaffolds Syk to phosphorylate BTK on tyrosine 551 via an interaction requiring the BTK SH2 domain, enhancing BTK kinase activity. BCR-induced BTK phosphorylation and activation are significantly reduced in BLNK-deficient and Syk-deficient B cells.\",\n      \"method\": \"Reconstitution cell system (co-expression), phosphorylation assays, BLNK-deficient and Syk-deficient B cell analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reconstitution system plus genetic loss-of-function validation in primary cells, multiple orthogonal approaches\",\n      \"pmids\": [\"11226282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"BTK adopts a compact autoinhibited conformation analogous to inactive c-Src and c-Abl, stabilized by cooperation of the PH-TH module with the SH2 and SH3 domains. Inositol hexakisphosphate (IP6) activates BTK by inducing transient PH-TH dimerization that promotes transphosphorylation of kinase domains; PIP3-containing membranes also activate BTK. This IP6-mediated activation mechanism is unique to BTK among Tec-family kinases.\",\n      \"method\": \"X-ray crystallography, biochemical activation assays, lipid-binding studies, mutagenesis\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure combined with in vitro biochemical reconstitution and mutagenesis in a single rigorous study\",\n      \"pmids\": [\"25699547\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Phosphorylation of BTK activation loop tyrosine Y551 by Src-family kinase Lyn is required for BTK kinase activity. The unphosphorylated isolated kinase domain is largely inactive, while Y551-phosphorylated kinase domain displays activity comparable to full-length BTK. BTK requires a second magnesium ion for catalytic activity.\",\n      \"method\": \"In vitro kinase assay, mass spectrometry phosphorylation mapping, Lyn-mediated in vitro phosphorylation of truncated BTK kinase domain, kinetic analysis\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with detailed kinetics and mass spectrometry validation\",\n      \"pmids\": [\"19206206\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"BTK is essential for B-cell development: genetic elimination of the pleckstrin homology (PH) or kinase domain abolishes BTK protein expression, causing reduced mature conventional B cells, severe B1 cell deficiency, serum IgM and IgG3 deficiency, and defective responses to B cell activators and thymus-independent type II antigens, recapitulating the Xid phenotype.\",\n      \"method\": \"Targeted gene knockout in mouse embryonic stem cells, RAG2-deficient blastocyst complementation, germline introduction, in vitro and in vivo immunological assays\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with specific molecular and cellular phenotypic readouts, replicated in two complementation strategies\",\n      \"pmids\": [\"7552994\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"BTK and Vav1 interact with and are recruited by the phagocytic receptor Dectin-1 to phagocytic cups containing Candida albicans; BTK colocalizes with PI(3,4,5)P3 and F-actin at phagocytic cups. BTK contributes to diacylglycerol (DAG) synthesis at the phagocytic cup and subsequent PKCε recruitment. BTK-deficient peritoneal macrophages and bone marrow-derived macrophages show reduced phagocytosis of C. albicans, and BTK-deficient mice are more susceptible to systemic C. albicans infection.\",\n      \"method\": \"Co-immunoprecipitation (Dectin-1 interactome), live-cell imaging/colocalization, selective BTK inhibitor, BTK-deficient macrophage phagocytosis assays, mouse infection model\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP, pharmacological inhibition, and genetic KO with specific cellular and in vivo phenotypes\",\n      \"pmids\": [\"23825946\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"BTK is required for TLR3-triggered NK cell activation: Btk-/- NK cells show decreased IFN-γ, perforin, and granzyme-B expression and reduced cytotoxic activity upon TLR3 stimulation. BTK promotes TLR3-triggered NK cell activation primarily by activating the NF-κB pathway. Btk-deficient XLA patients also show reduced TLR3-triggered human NK cell activation.\",\n      \"method\": \"Btk knockout mouse NK cell functional assays, in vivo BTK inhibitor administration, adoptive transfer experiments, patient NK cell analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with specific mechanistic pathway placement (NF-κB) confirmed in both mouse and human cells\",\n      \"pmids\": [\"22589540\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"BTK functions as a dual regulator of apoptosis: it promotes radiation-induced (oxidative stress) apoptosis partly by down-regulating STAT-3 anti-apoptotic activity, while inhibiting Fas-activated apoptosis by associating with death receptor Fas and impairing its interaction with FADD, thereby preventing assembly of the death-inducing signaling complex (DISC).\",\n      \"method\": \"Biochemical interaction studies (BTK-Fas association), apoptosis assays, STAT-3 activity measurements\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single lab, mechanistic claims supported by biochemical interaction data but limited orthogonal validation\",\n      \"pmids\": [\"9751072\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"BTK phosphorylates and stabilizes p53 in response to DNA damage, creating a positive feedback loop that increases p53 protein levels and enhances transactivation of p53 target genes. BTK inhibition reduces both p53-dependent senescence and apoptosis.\",\n      \"method\": \"BTK knockdown/inhibition assays, p53 phosphorylation measurements, senescence and apoptosis readouts, DNA damage assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple cellular readouts but from single lab; no in vitro reconstitution of direct phosphorylation\",\n      \"pmids\": [\"27630139\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Endogenous BTK and Akt interact with each other in B cells, and this interaction is inducible following H2O2 stimulation. PI3K and BTK are involved in Akt phosphorylation following oxidative stress, and BTK modulates both ERK and JNK phosphorylation downstream of PI3K.\",\n      \"method\": \"Co-immunoprecipitation of endogenous proteins in DT40 and Nalm6 B cells, co-localization imaging in COS-7 cells, PI3K inhibitor studies\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single Co-IP with partial mechanistic follow-up; interaction is endogenous but single lab\",\n      \"pmids\": [\"12054657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Kinase-dead BTK mutants C481F and C481Y confer ibrutinib resistance through a kinase-independent scaffold mechanism: upon BCR activation, Src family kinases phosphorylate Y551 on these mutants, which then recruit HCK via its SH2 domain, disrupting HCK autoinhibition and leading to HCK-mediated PLCγ2 phosphorylation and NF-κB activation.\",\n      \"method\": \"In vitro kinase assays, structural modeling, co-immunoprecipitation (BTK mutant-HCK interaction), BCR signaling assays, clonogenic proliferation assays\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro kinase assays, direct pulldown of HCK by BTK mutants, structural modeling, and functional signaling validation\",\n      \"pmids\": [\"35639855\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Certain drug-resistant BTK mutations (e.g., L528W/kinase-dead mutants) impair BTK enzymatic activity while imparting novel protein-protein interactions that sustain BCR signaling, revealing an oncogenic scaffold function of mutant BTK independent of its kinase activity.\",\n      \"method\": \"Biochemical characterization of mutant BTK enzymatic activities, protein-protein interaction studies, BCR signaling assays, clinical BTK degrader (NX-2127) proteolysis achieving >80% BTK degradation in patients\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — enzymatic assays, protein interaction studies, and clinical proof-of-concept degradation data in multiple orthogonal experiments\",\n      \"pmids\": [\"38301010\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Pirtobrutinib (a noncovalent BTK inhibitor) stabilizes BTK in a closed, inactive conformation and prevents Y551 phosphorylation in the activation loop, a mechanism distinct from covalent BTKis. It inhibits both wild-type BTK and C481 substitution mutants with similar potency via an extensive network of interactions in the ATP-binding region without direct contact with C481.\",\n      \"method\": \"Differential scanning fluorimetry, enzymatic and cell-based assays, structural binding analysis, in vitro kinase assays, xenograft tumor models\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biophysical, structural, and enzymatic characterization with multiple orthogonal methods in a single comprehensive study\",\n      \"pmids\": [\"36796019\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"BTK C481S mutation drives ibrutinib resistance through reactivation of the BTK-PLCγ2-ERK1/2 signaling axis in the presence of ibrutinib, and ERK1/2-dependent release of IL-6 and IL-10 by BTK-C481S-expressing cells can protect wild-type BTK-expressing cells in a paracrine manner.\",\n      \"method\": \"Engineered BTK C481S and BTKWT cell lines, ERK1/2 inhibitor studies, Transwell co-culture system, IL-6/IL-10 blocking antibodies, signaling assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — engineered isogenic cell lines with pharmacological and antibody blocking confirmation of mechanism, multiple orthogonal approaches\",\n      \"pmids\": [\"29496671\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BTK is activated in human neutrophils upon fungal exposure in a TLR2-, Dectin-1-, and FcγR-dependent manner, triggering the oxidative burst. BTK inhibition selectively impairs neutrophil-mediated damage to Aspergillus hyphae, primary granule release, and the fungus-induced oxidative burst by abrogating NADPH oxidase subunit p40phox and GTPase RAC2 activation. Neutrophil-specific Btk deletion in mice enhances aspergillosis susceptibility.\",\n      \"method\": \"Patient neutrophil functional assays (XLA patients and BTKi-treated patients), neutrophil-specific conditional Btk knockout mice, p40phox and RAC2 activation assays, in vivo aspergillosis model\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-type specific conditional KO, human genetic disease validation, and mechanistic pathway identification (p40phox/RAC2) with multiple orthogonal approaches\",\n      \"pmids\": [\"38696257\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BTK is a required signaling node downstream of Fc receptors for microglial proliferative responses: microglia proliferation is amplified in BtkE41K (constitutively active) knock-in mice and blunted by CNS-penetrant BTK inhibitor treatment. The proliferative response is dependent on central Fc receptor engagement.\",\n      \"method\": \"BtkE41K knock-in mice, CNS-penetrant BTK inhibitor treatment, anti-MOG antibody in vivo model, Fcγ receptor knockout mice\",\n      \"journal\": \"Brain : a journal of neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function knock-in and pharmacological inhibition with specific cellular phenotype, multiple genetic controls\",\n      \"pmids\": [\"34145876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Follicular lymphoma-associated inactivating BTK mutations destabilize BTK protein and create kinase-dead mutants that do not reduce PLCγ2 phosphorylation but instead cause exaggerated AKT phosphorylation following BCR crosslinking via a PI3Kδ-dependent mechanism. BTK knockdown or degradation in non-malignant B cells similarly results in enhanced BCR-induced AKT activation.\",\n      \"method\": \"Reconstitution of WT and mutant BTK in engineered lymphoma cell lines, shRNA knockdown, PROTAC-mediated BTK degradation, primary follicular lymphoma B cell signaling assays, PI3Kδ inhibitor treatment\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reconstitution of mutants, genetic knockdown, pharmacological degradation, and primary patient cell validation with multiple orthogonal approaches\",\n      \"pmids\": [\"33419778\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"A systematic BTK mutagenesis screen identified a gatekeeper residue (T474) and kinase domain mutations (L512M, E513G, F517L, L547P); co-occurrence of gatekeeper and kinase domain mutations in cis results in 10- to 15-fold gain of BTK kinase activity and de novo transforming potential in vitro and in vivo. Computational structural analyses reveal these lesions disrupt an intramolecular autoinhibitory mechanism.\",\n      \"method\": \"Systematic mutagenesis screen, in vitro transformation assays, in vivo xenograft models, computational BTK structural analysis\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — systematic mutagenesis with both in vitro and in vivo functional validation and structural modeling\",\n      \"pmids\": [\"31217352\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BCR-induced phosphorylation of MARCKS (myristoylated alanine-rich C-kinase substrate) is reduced by BTK inhibitors in CLL cells. MARCKS sequesters PI(4,5)P2 and affects BCR clustering; genetically induced MARCKS loss significantly increases AKT signaling and migratory capacity of CLL cells.\",\n      \"method\": \"Phosphoproteomic analysis under ibrutinib treatment, genetic loss-of-MARCKS studies, AKT signaling assays, migration assays, patient clinical correlation\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — phosphoproteomics plus genetic loss-of-function with defined signaling and cellular phenotypes, single lab\",\n      \"pmids\": [\"33735912\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Primary resistance to BTK inhibitors in ABC-DLBCL is driven by epigenetic changes mediated in part by transcription factor TCF4, resulting in a phenotypic shift where GTPase RAC2 substitutes for BTK in activating PLCγ2 and sustaining NF-κB activity. RAC2-PLCγ2 interaction is also increased in CLL cells from patients with persistent/progressive disease on BTK inhibitor treatment.\",\n      \"method\": \"Ibrutinib resistance modeling in ABC-DLBCL cell lines, transcription factor analysis, epistasis studies, RAC2-PLCγ2 co-immunoprecipitation, primary patient CLL cells\",\n      \"journal\": \"Blood cancer discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell line modeling plus primary patient validation with mechanistic pathway placement of RAC2 as BTK bypass, multiple methods\",\n      \"pmids\": [\"34778802\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Covalent BTK inhibitor QL47 modifies Cys481 in the BTK kinase domain, inhibits BTK autophosphorylation on Tyr223, inhibits phosphorylation of downstream effector PLCγ2 (Tyr759), induces G1 cell cycle arrest, and causes pronounced degradation of BTK protein in Ramos B cells.\",\n      \"method\": \"Structure-based drug design, in vitro kinase assay (IC50=7nM), cellular autophosphorylation and PLCγ2 phosphorylation assays, cell cycle analysis, Western blot\",\n      \"journal\": \"ACS chemical biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro kinase assay plus cellular mechanistic validation, single lab study\",\n      \"pmids\": [\"24556163\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BTK is a cytoplasmic Tec-family tyrosine kinase that is maintained in an autoinhibited compact conformation (stabilized by PH-TH, SH2, and SH3 domain interactions) and is activated downstream of BCR, TLR, FcR, and Dectin-1 by membrane recruitment via PIP3-bound PH domain, Lyn-mediated transphosphorylation of the activation loop at Y551, and BLNK-scaffolded Syk-dependent phosphorylation, ultimately propagating BCR signals through PLCγ2 to NF-κB, NFAT, and Ca2+ mobilization; additionally, BTK functions as a kinase-independent scaffold in certain drug-resistant mutant contexts, acts as a direct activator of NLRP3 inflammasome and p53, and plays roles in NK cell TLR3 signaling, macrophage phagocytosis via Dectin-1/Vav1, neutrophil oxidative burst (p40phox/RAC2 activation), and microglial FcR-dependent proliferative responses.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"BTK was identified as the gene defective in X-linked agammaglobulinemia (XLA); it encodes a cytoplasmic protein-tyrosine kinase expressed in B cells and belonging to the Src family of proto-oncogenes.\",\n      \"method\": \"Positional cloning, mutation analysis in XLA families, expression studies\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original positional cloning with mutation validation, foundational discovery replicated independently\",\n      \"pmids\": [\"8380905\", \"8425221\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"The pleckstrin homology (PH) domain of BTK directly interacts with protein kinase C (PKC) isoforms (alpha, beta I, beta II, epsilon, zeta) in mast cells; PKC phosphorylates BTK and down-regulates its enzymatic activity.\",\n      \"method\": \"GST-fusion pulldown with mast cell lysates, co-immunoprecipitation from intact cells, in vitro kinase assay, PKC depletion/inhibition experiments\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro binding, in vivo co-IP, and functional kinase assays with multiple PKC isoforms\",\n      \"pmids\": [\"7522330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"The PH domain of BTK binds the beta-gamma dimer of heterotrimeric G proteins in vitro and in vivo; a conserved tryptophan in subdomain 6 of the PH domain is critical for this interaction, linking BTK to G-protein-coupled signaling.\",\n      \"method\": \"In vitro binding assay, in vivo competition assay, site-directed mutagenesis of PH domain tryptophan\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro and in vivo binding with mutagenesis identifying critical residue\",\n      \"pmids\": [\"7972043\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"BTK mRNA and protein are expressed broadly in hematopoietic lineages (B cells, monocytes, mast cells, myeloid cells) but are selectively down-regulated in T lymphocytes and plasma cells.\",\n      \"method\": \"Northern blotting, immunoprecipitation, Western blotting, PCR-based analysis across diverse cell lines and primary cells\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods across many cell types, replicated pattern\",\n      \"pmids\": [\"8283037\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Genetic ablation of BTK's PH or kinase domain in mice causes reduced conventional B cell numbers, severe B1 cell deficiency, serum IgM/IgG3 deficiency, and defective responses to thymus-independent type II antigens, recapitulating the Xid phenotype and proving BTK is required for B lymphocyte development and activation.\",\n      \"method\": \"Targeted gene disruption in ES cells (deletion of PH or kinase domain), RAG2-deficient blastocyst complementation, germline introduction; in vitro and in vivo immunological assays\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — rigorous genetic loss-of-function with multiple phenotypic readouts, complementation experiments\",\n      \"pmids\": [\"7552994\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"BTK is activated by SRC family kinases through transphosphorylation at tyrosine 551 (Y551) in the kinase activation loop; this leads to BTK autophosphorylation at a second site and membrane association of the activated kinase. The same two sites are phosphorylated upon BCR cross-linking.\",\n      \"method\": \"In vitro kinase assay, phosphopeptide mapping, site-directed mutagenesis, cell-based BCR crosslinking with phosphorylation analysis\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro biochemical reconstitution with mutagenesis and in vivo receptor stimulation, replicated\",\n      \"pmids\": [\"8629002\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The major BTK autophosphorylation site is Y223 within the SH3 domain; mutation of Y223 to F blocks autophosphorylation and potentiates the transforming activity of the gain-of-function Btk* (E41K) mutant, indicating that autophosphorylation at Y223 negatively regulates SH3-mediated signaling.\",\n      \"method\": \"Phosphopeptide mapping, site-directed mutagenesis (Y223F), fibroblast transformation assay, co-expression with Src kinase\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis with functional transformation readout, mechanistic mapping of autophosphorylation site\",\n      \"pmids\": [\"8630736\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"BTK promotes radiation-induced apoptosis (pro-apoptotic via down-regulation of STAT3 anti-apoptotic activity) but inhibits Fas-activated apoptosis by associating with the death receptor Fas and impairing its interaction with FADD, thereby preventing assembly of the death-inducing signaling complex (DISC).\",\n      \"method\": \"Co-immunoprecipitation (BTK-Fas interaction), functional apoptosis assays, STAT3 activity measurements\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — co-IP with functional apoptosis assays, single lab, mechanistic follow-up\",\n      \"pmids\": [\"9751072\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"BCAP (B cell adaptor for PI3K) is tyrosine-phosphorylated by both Syk and BTK downstream of BCR engagement; phosphorylated BCAP binds the p85 subunit of PI3K and recruits PI3K to lipid rafts (GEMs), mediating PIP3 generation and Akt activation.\",\n      \"method\": \"BCAP gene disruption in DT40 cells, co-immunoprecipitation, PIP3 measurement, Akt phosphorylation assay, subcellular fractionation\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genetic KO with multiple orthogonal biochemical readouts, clear pathway placement of BTK\",\n      \"pmids\": [\"11163197\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"BLNK (B cell linker protein) mediates Syk-dependent BTK activation: BLNK allows Syk to phosphorylate BTK at Y551 through a BLNK–BTK SH2 domain interaction, thereby enhancing BTK activity. BCR-induced BTK phosphorylation and activation are significantly reduced in BLNK-deficient B cells.\",\n      \"method\": \"Reconstitution cell system with co-expression experiments, BCR-induced phosphorylation assays in BLNK-deficient and Syk-deficient B cells, SH2-domain interaction analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reconstitution in cells plus genetic deficiency models, mechanistic identification of scaffold role of BLNK\",\n      \"pmids\": [\"11226282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Endogenous BTK and Akt interact with each other in B cells, and this interaction is inducible by H2O2 stimulation; BTK and Akt co-localize in the perinuclear region and membrane ruffles, and BTK is involved in PI3K-dependent Akt phosphorylation following oxidative stress.\",\n      \"method\": \"Co-immunoprecipitation from DT40 and Nalm6 B cells, confocal co-localization in COS-7 cells, PI3K inhibition experiments, phosphorylation assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — reciprocal co-IP plus co-localization in multiple cell lines, single lab\",\n      \"pmids\": [\"12054657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"BTK binds directly to the Toll/IL-1 receptor (TIR) domains of TLR4, TLR6, TLR8, and TLR9, as well as to the TLR adaptor proteins MyD88, Mal, and IRAK-1 (but not TRAF-6); BTK is activated (tyrosine-phosphorylated) by LPS/TLR4 stimulation and is required for TLR4-mediated NF-κB activation.\",\n      \"method\": \"Co-immunoprecipitation, dominant-negative BTK expression, NF-κB reporter assay, kinase activity assay, BTK-specific inhibitor (LFM-A13) experiments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple interaction assays with functional NF-κB readout, genetic and pharmacologic inhibition, replicated across cell lines\",\n      \"pmids\": [\"12724322\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"BTK phosphorylates the TLR adaptor protein Mal, which then interacts with SOCS-1, leading to Mal polyubiquitination and degradation. This negative-feedback mechanism limits TLR2/TLR4-dependent NF-κB activation.\",\n      \"method\": \"Co-immunoprecipitation, phosphorylation assays, ubiquitination assays, genetic KO and overexpression of SOCS-1, NF-κB reporter assays\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal biochemical and genetic approaches establishing direct substrate relationship and functional consequence\",\n      \"pmids\": [\"16415872\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Activation loop phosphorylation at Y551 by Src-family kinase Lyn is required for BTK kinase domain activity: the isolated kinase domain is largely inactive without Y551 phosphorylation; in vitro phosphorylation restores full activity comparable to full-length BTK. BTK also requires a second Mg2+ ion for activity.\",\n      \"method\": \"In vitro kinase reconstitution using Lyn-mediated phosphorylation of isolated BTK kinase domain, mass spectrometry phosphorylation mapping, kinetic analysis, divalent metal dependence studies\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with detailed kinetic analysis and mass spectrometry, rigorous mechanistic study\",\n      \"pmids\": [\"19206206\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"BTK is required for NK cell activation via the TLR3 pathway; Btk-/- murine NK cells show decreased IFN-γ, perforin, and granzyme-B expression and reduced cytotoxicity; BTK promotes TLR3-triggered NK cell activation mainly by activating the NF-κB pathway. BTK-deficient (XLA) human NK cells also show reduced TLR3-triggered activation.\",\n      \"method\": \"Btk knockout mouse studies, adoptive transfer experiments, in vivo BTK inhibitor administration, XLA patient NK cell functional assays, cytokine and surface marker measurements\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with multiple functional readouts, human XLA patient validation, in vivo model\",\n      \"pmids\": [\"22589540\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"BTK and Vav1 are recruited to phagocytic cups during Dectin-1-mediated phagocytosis of Candida albicans in macrophages; BTK co-localizes with PI(3,4,5)P3 and F-actin at the cup; BTK contributes to DAG synthesis and subsequent PKCε recruitment at the phagocytic cup; BTK- or Vav1-deficient macrophages show impaired phagocytosis and mice are more susceptible to systemic C. albicans infection.\",\n      \"method\": \"Co-immunoprecipitation (Dectin-1 interactors), fluorescence microscopy/live imaging, selective BTK inhibitor, BTK- and Vav1-deficient mouse macrophages (peritoneal and bone-marrow-derived), in vivo infection model\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct localization with functional consequence, genetic KO validation in vitro and in vivo, pharmacological confirmation\",\n      \"pmids\": [\"23825946\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Ibrutinib (PCI-32765) irreversibly inhibits BTK by covalently modifying Cys481; resistance in CLL arises from a C481S mutation at this site (making BTK only reversibly inhibited) or from gain-of-function mutations in downstream PLCγ2 (R665W, L845F) that produce autonomous BCR activity.\",\n      \"method\": \"Whole-exome sequencing at baseline and relapse, functional analysis of C481S mutation, Ion Torrent targeted sequencing\",\n      \"journal\": \"The New England journal of medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — functional characterization of resistance mutations with genetic sequencing and in vitro validation, widely replicated\",\n      \"pmids\": [\"24869598\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"BTK is an essential component of the NLRP3 inflammasome: BTK physically interacts with both ASC and NLRP3; pharmacological or genetic inhibition of BTK severely impairs NLRP3 inflammasome activation, caspase-1 cleavage, and IL-1β secretion. In a mouse brain ischemia model, ibrutinib suppresses infarct volume and neurological damage by inhibiting inflammasome-mediated IL-1β maturation in infiltrating macrophages and neutrophils.\",\n      \"method\": \"Co-immunoprecipitation (BTK-ASC and BTK-NLRP3), pharmacological BTK inhibition (ibrutinib), genetic BTK-deficient mice, mouse brain ischemia/reperfusion model, caspase-1 and IL-1β assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct protein-protein interactions demonstrated by co-IP, genetic and pharmacologic loss-of-function with clear functional readouts, in vivo model\",\n      \"pmids\": [\"26059659\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"BTK drives macrophage polarization toward a TH2 phenotype in pancreatic ductal adenocarcinoma (PDAC) via a B cell–macrophage cross-talk involving FcRγ+ tumor-associated macrophages and PI3Kγ-dependent BTK activation; BTK inhibition with ibrutinib reprograms macrophages toward TH1 and restores CD8+ T-cell cytotoxicity against PDAC.\",\n      \"method\": \"BTK inhibitor (ibrutinib) in PDAC mouse models, PI3Kγ inhibition, macrophage phenotyping, T-cell functional assays, tumor growth measurements\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic and pharmacologic epistasis establishing BTK's role in immune cross-talk with defined cellular phenotype\",\n      \"pmids\": [\"26715645\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Autoinhibited BTK adopts a compact inactive conformation (analogous to c-Src and c-Abl) stabilized by the PH-TH module together with SH2 and SH3 domains; inositol hexakisphosphate (IP6) activates BTK by inducing transient PH-TH dimerization that promotes transphosphorylation of kinase domains. PIP3-containing membranes also activate BTK by a related mechanism.\",\n      \"method\": \"X-ray crystallography of BTK domains, biochemical activity assays, IP6 binding experiments, mutagenesis of PH-TH interface\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structures combined with biochemical validation and mutagenesis in a single rigorous study\",\n      \"pmids\": [\"25699547\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"BTK phosphorylates p53 in response to DNA damage, creating a positive feedback loop that increases p53 protein levels and enhances transactivation of p53 target genes; BTK induction leads to enhanced p53-dependent senescence and apoptosis, while BTK inhibition reduces both responses.\",\n      \"method\": \"BTK inhibition and overexpression in cell lines, DNA damage assays, p53 phosphorylation analysis, senescence assays, apoptosis assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — functional assays with phosphorylation readout, single lab, limited mechanistic dissection of direct vs. indirect phosphorylation\",\n      \"pmids\": [\"27630139\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The BTK C481S mutation drives ibrutinib resistance via reactivation of BTK–PLCγ2–ERK1/2 signaling; ibrutinib-treated BTKCys481Ser cells release pro-survival cytokines IL-6 and IL-10 through an ERK1/2-dependent mechanism, and these cytokines protect BTK-wild-type MYD88-mutated cells from ibrutinib via a paracrine mechanism.\",\n      \"method\": \"Engineered BTKCys481Ser-expressing cell lines, ERK1/2 inhibitor experiments, Transwell co-culture system, IL-6/IL-10 blocking antibodies, serum cytokine analysis in WM patients\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (engineered cells, inhibitors, antibody blocking, patient samples) in single study establishing paracrine mechanism\",\n      \"pmids\": [\"29496671\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Noncovalent BTK inhibitors reveal that the gatekeeper residue T474 and kinase domain residues (L512M, E513G, F517L, L547P) are critical for BTK activity; co-occurrence of gatekeeper and kinase domain mutations in cis produces 10-15-fold gain of BTK kinase activity and de novo transforming potential, disrupting an intramolecular autoinhibitory mechanism.\",\n      \"method\": \"Systematic BTK mutagenesis screen, in vitro transformation assays, in vivo xenograft models, computational structural analysis\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — systematic mutagenesis with in vitro and in vivo functional validation and structural modeling\",\n      \"pmids\": [\"31217352\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BTK is a required signaling node downstream of Fc receptors in microglia: MOG autoantibody-induced microglial proliferation is amplified in BtkE41K constitutively-active knock-in mice and blunted by a CNS-penetrant BTK inhibitor; this establishes BTK as mediating FcR-driven microglial responses in the CNS.\",\n      \"method\": \"In vivo MOG antibody injection model, FcγR knockout mice, BtkE41K knock-in mice, CNS-penetrant BTK inhibitor treatment, microglial proliferation and gene expression assays\",\n      \"journal\": \"Brain\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function and loss-of-function genetic models with pharmacologic confirmation and in vivo phenotypic readouts\",\n      \"pmids\": [\"34145876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In ABC-DLBCL, primary resistance to BTK inhibitor ibrutinib is epigenetic: the transcription factor TCF4 drives a phenotypic shift in which RAC2 substitutes for BTK to activate PLCγ2 and sustain NF-κB signaling; elevated RAC2–PLCγ2 interaction was also observed in CLL cells from patients with persistent disease on BTK inhibitors.\",\n      \"method\": \"Ibrutinib resistance modeling in DLBCL cells, transcriptomic and epigenetic profiling, RNAi/genetic perturbation, biochemical interaction assays, patient CLL cell analysis\",\n      \"journal\": \"Blood cancer discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multi-method study establishing bypass mechanism, patient validation, but single lab\",\n      \"pmids\": [\"34778802\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"MARCKS is a BTK substrate in CLL cells: BCR stimulation induces MARCKS phosphorylation that is reduced by BTK inhibitors; MARCKS sequesters PIP2 and affects BCR clustering; genetic loss of MARCKS increases AKT signaling and migratory capacity of CLL cells.\",\n      \"method\": \"Phosphoproteomic analysis under ibrutinib treatment, MARCKS genetic knockdown, AKT signaling assays, migration assays, clinical correlation with acalabrutinib treatment\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — phosphoproteomics plus genetic KD with functional readouts, patient correlation\",\n      \"pmids\": [\"33735912\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Kinase-dead BTK mutants C481F and C481Y maintain BCR signaling by physically recruiting hematopoietic cell kinase (HCK): Src family kinases phosphorylate mutant BTK at Y551, which engages HCK's SH2 domain, disrupts HCK's autoinhibition, and activates HCK to phosphorylate PLCγ2, sustaining NF-κB signaling and clonogenic proliferation independently of BTK kinase activity.\",\n      \"method\": \"In vitro kinase assays confirming kinase-dead status, structural modeling, co-immunoprecipitation (BTK-HCK), phosphorylation assays, BCR signaling pathway analysis, clonogenic assay\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro kinase assays, co-IP, structural modeling, and functional assays identifying scaffold mechanism\",\n      \"pmids\": [\"35639855\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Pirtobrutinib (a noncovalent BTK inhibitor) stabilizes BTK in a closed, inactive conformation through an extensive interaction network in the ATP-binding region that does not contact C481; it prevents Y551 phosphorylation in the activation loop and inhibits both wild-type and C481-mutant BTK with similar potencies.\",\n      \"method\": \"Differential scanning fluorimetry, enzymatic inhibition assays, cell-based phosphorylation assays, in vivo xenograft models, kinome selectivity profiling\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — biophysical and biochemical characterization with structural and functional validation across multiple assay formats\",\n      \"pmids\": [\"36796019\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Some drug-resistant BTK mutants (including kinase-impaired forms) sustain BCR signaling through novel protein-protein interactions that scaffold downstream effectors independently of BTK kinase activity; NX-2127, a BTK/IKZF1/3 degrader, can bind and proteasomally degrade each mutant BTK proteoform, achieving >80% BTK degradation in CLL patients and potent BCR signaling blockade.\",\n      \"method\": \"Characterization of acquired resistance mutations, in vitro enzymatic activity assays, protein-protein interaction studies, PROTAC-mediated degradation assays, clinical treatment with NX-2127\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple biochemical assays plus clinical proof-of-concept, identifying scaffold function of mutant BTK\",\n      \"pmids\": [\"38301010\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BTK drives antifungal immunity in neutrophils: upon fungal exposure, BTK is activated in human neutrophils via TLR2, Dectin-1, and FcγR signaling, triggering the oxidative burst; BTK inhibition selectively blocks Aspergillus hyphal damage and primary granule release by abrogating NADPH oxidase subunit p40phox and GTPase RAC2 activation; neutrophil-specific Btk deletion in mice enhances aspergillosis susceptibility.\",\n      \"method\": \"Human neutrophil activation assays, BTK inhibitor treatment, XLA patient neutrophil studies, neutrophil-specific Btk conditional KO mice, p40phox and RAC2 activation assays, in vivo aspergillosis model, GM-CSF rescue experiments\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic conditional KO with multiple functional readouts, human patient validation, in vivo infection model\",\n      \"pmids\": [\"38696257\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BTK is a cytoplasmic Tec-family tyrosine kinase that is activated downstream of multiple receptors (BCR, TLRs, FcRs, Dectin-1, G-protein-coupled receptors) through a two-step phosphorylation mechanism: Src-family kinases (e.g., Lyn) transphosphorylate the activation loop at Y551, followed by BTK autophosphorylation at Y223 in the SH3 domain; membrane recruitment via PH domain binding to PIP3 (or IP6-induced PH-TH dimerization) is essential for activation; activated BTK phosphorylates substrates including PLCγ2, BCAP, Mal, p53, and MARCKS to regulate Ca2+ flux, NF-κB, PI3K-Akt, and NLRP3 inflammasome pathways, controlling B cell development, survival, and innate immune effector functions in macrophages, NK cells, neutrophils, and microglia; drug-resistant BTK mutations can render the kinase catalytically inactive while preserving oncogenic scaffold functions through recruitment of alternative kinases (HCK) or novel protein-protein interactions, which are overcome by PROTAC-mediated BTK degradation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"BTK is a Tec-family cytoplasmic tyrosine kinase essential for B-cell development and innate immune signaling through B-cell receptors (BCR), Toll-like receptors, Fc receptors, and Dectin-1. BTK is maintained in a compact autoinhibited conformation stabilized by PH-TH, SH2, and SH3 domain interactions and is activated by PIP3-mediated membrane recruitment, BLNK/Syk-dependent scaffolding, and Lyn-mediated transphosphorylation at Y551, whereupon it phosphorylates PLCγ2 to propagate signals through NF-κB, ERK, and Ca²⁺ pathways [PMID:25699547, PMID:11226282, PMID:19206206]. Beyond BCR signaling, BTK drives neutrophil NADPH oxidase activation via p40phox/RAC2, macrophage Dectin-1-dependent phagocytosis, TLR3-triggered NK cell cytotoxicity, and FcR-dependent microglial proliferation [PMID:38696257, PMID:23825946, PMID:22589540, PMID:34145876]. Loss-of-function BTK mutations cause X-linked agammaglobulinemia (XLA) with arrested B-cell development, while drug-resistant kinase-dead mutants (C481S/F/Y, L528W) can sustain oncogenic BCR signaling through a kinase-independent scaffold mechanism that recruits HCK to phosphorylate PLCγ2 [PMID:7552994, PMID:35639855, PMID:38301010].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Establishing that BTK is indispensable for B-cell development resolved whether this kinase had a non-redundant role in humoral immunity: targeted deletion of the PH or kinase domain abolished mature B-cell and B1-cell generation and recapitulated the Xid immunodeficiency phenotype.\",\n      \"evidence\": \"Targeted gene knockout in mice with RAG2-deficient blastocyst complementation and germline transmission, in vitro/in vivo immunological assays\",\n      \"pmids\": [\"7552994\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling targets in developing B cells not defined\", \"Mechanism of B1-cell-specific dependence unresolved\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Discovery that BTK dually regulates apoptosis—promoting radiation-induced death via STAT-3 suppression while inhibiting Fas-mediated death through FADD displacement—revealed context-dependent survival functions beyond BCR signaling.\",\n      \"evidence\": \"Biochemical BTK-Fas association studies, apoptosis assays, STAT-3 activity measurements\",\n      \"pmids\": [\"9751072\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"BTK-Fas interaction not confirmed by reciprocal approaches in other labs\", \"Physiological relevance of STAT-3 suppression in primary B cells not established\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identification of BLNK as the scaffold that positions Syk to phosphorylate BTK at Y551 answered how BCR engagement activates BTK and placed BTK downstream of the Syk-BLNK axis.\",\n      \"evidence\": \"Co-expression reconstitution, phosphorylation assays, BLNK-deficient and Syk-deficient B-cell analysis\",\n      \"pmids\": [\"11226282\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and dynamics of the BLNK-Syk-BTK complex at the membrane not resolved\", \"Whether other scaffolds can substitute for BLNK unclear\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Observation that BTK and Akt form an endogenous, H₂O₂-inducible complex in B cells suggested BTK integrates oxidative stress with PI3K-Akt and MAPK signaling.\",\n      \"evidence\": \"Co-immunoprecipitation of endogenous proteins in DT40 and Nalm6 B cells, PI3K inhibitor studies\",\n      \"pmids\": [\"12054657\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether BTK directly phosphorylates Akt not tested\", \"Functional consequence of the BTK-Akt complex on cell fate not delineated\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Biochemical demonstration that Y551 phosphorylation by Lyn converts the intrinsically inactive kinase domain to full catalytic competence established the activation-loop switch as the primary gating event for BTK enzymatic function.\",\n      \"evidence\": \"In vitro kinase assay with truncated and full-length BTK, mass spectrometry phosphorylation mapping, kinetic analysis\",\n      \"pmids\": [\"19206206\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Contribution of autophosphorylation at Y223 to sustained activity not fully dissected\", \"Dual-magnesium requirement not structurally visualized\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstrating that Btk-knockout NK cells have impaired TLR3-triggered cytotoxicity and NF-κB activation—validated in XLA patient cells—extended BTK's functional reach beyond B cells into innate lymphocyte antiviral responses.\",\n      \"evidence\": \"Btk-KO mouse NK cell assays, in vivo BTK inhibitor administration, XLA patient NK cell analysis\",\n      \"pmids\": [\"22589540\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct BTK substrates in TLR3 signaling not identified\", \"Relative contribution of BTK kinase activity versus scaffold function in NK cells unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Showing that BTK is recruited to Dectin-1 phagocytic cups alongside PIP3 and Vav1, where it drives DAG/PKCε signaling and efficient phagocytosis of Candida, established BTK as a critical node in macrophage antifungal innate immunity.\",\n      \"evidence\": \"Co-immunoprecipitation, live-cell imaging, BTK-deficient macrophage assays, in vivo Candida infection model\",\n      \"pmids\": [\"23825946\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BTK directly phosphorylates Vav1 at the phagocytic cup not shown\", \"Downstream signaling to the phagolysosome maturation pathway not delineated\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Solving the crystal structure of full-length autoinhibited BTK and discovering IP6-induced PH-TH dimerization as a unique activation trigger answered how BTK transitions from compact inactive state to active transphosphorylating dimers.\",\n      \"evidence\": \"X-ray crystallography, biochemical activation assays, lipid-binding studies, mutagenesis\",\n      \"pmids\": [\"25699547\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological IP6 concentrations required for activation not established in cells\", \"Full-length activated-state structure not yet determined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Characterizing the C481S ibrutinib-resistance mutation revealed that it reactivates the BTK-PLCγ2-ERK1/2 axis and enables paracrine protection of wild-type cells via IL-6/IL-10, explaining clinical clonal coexistence.\",\n      \"evidence\": \"Engineered isogenic BTK-C481S cell lines, ERK inhibitor studies, Transwell co-culture, IL-6/IL-10 blocking antibodies\",\n      \"pmids\": [\"29496671\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo validation of the paracrine protection model not provided\", \"Whether other cytokines contribute to bystander protection not systematically assessed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"A systematic mutagenesis screen uncovering that co-occurring gatekeeper (T474) and kinase-domain mutations produce 10–15-fold gain of kinase activity with transforming potential mapped the intramolecular autoinhibitory constraints that prevent oncogenic activation.\",\n      \"evidence\": \"Systematic mutagenesis screen, in vitro transformation assays, in vivo xenograft models, computational structural analysis\",\n      \"pmids\": [\"31217352\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether such compound mutations arise clinically under therapeutic pressure not documented\", \"Structural basis of synergy between gatekeeper and distal mutations not experimentally resolved at atomic level\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Multiple studies converged to reveal that loss of BTK kinase activity—whether by follicular lymphoma mutations, shRNA knockdown, or PROTAC degradation—paradoxically enhances PI3Kδ-dependent AKT activation after BCR crosslinking, uncovering a negative-regulatory role of catalytically active BTK on the PI3K-AKT axis.\",\n      \"evidence\": \"Reconstitution of WT/mutant BTK in lymphoma lines, shRNA knockdown, PROTAC degradation, primary FL B-cell signaling assays, PI3Kδ inhibitor rescue\",\n      \"pmids\": [\"33419778\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which active BTK restrains PI3Kδ-AKT signaling not molecularly defined\", \"Relevance to other B-cell malignancies with BTK loss not tested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identifying BTK as the Fc receptor-coupled kinase driving antibody-dependent microglial proliferation, amplified in gain-of-function BtkE41K mice and suppressed by CNS-penetrant BTK inhibitors, positioned BTK as a therapeutic target in neuroinflammation.\",\n      \"evidence\": \"BtkE41K knock-in mice, CNS-penetrant BTK inhibitor, anti-MOG antibody in vivo model, FcγR-KO mice\",\n      \"pmids\": [\"34145876\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct BTK substrates in microglia not identified\", \"Whether microglial BTK signals through PLCγ2 or distinct effectors not determined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Demonstrating that kinase-dead C481F/Y BTK mutants recruit and activate HCK via their pY551-SH2 interface to sustain PLCγ2/NF-κB signaling established a kinase-independent scaffold mechanism for ibrutinib resistance.\",\n      \"evidence\": \"In vitro kinase assays, co-immunoprecipitation, structural modeling, BCR signaling and clonogenic proliferation assays\",\n      \"pmids\": [\"35639855\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other SFK members besides HCK can be recruited by scaffold BTK not tested\", \"Structural basis of HCK autoinhibition disruption by BTK not experimentally resolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Extending the scaffold paradigm, clinical-grade BTK degrader NX-2127 achieved >80% BTK protein elimination in patients, validating that even kinase-dead drug-resistant BTK mutants depend on protein-level presence for oncogenic signaling.\",\n      \"evidence\": \"Biochemical characterization of mutant BTK activities, protein-protein interaction studies, clinical BTK degrader proteolysis data\",\n      \"pmids\": [\"38301010\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Long-term clinical efficacy and resistance to degrader-based strategies not established\", \"Full interactome of scaffold-mode BTK mutants not catalogued\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defining BTK as the kinase that activates neutrophil NADPH oxidase through p40phox and RAC2 downstream of TLR2/Dectin-1/FcγR resolved why XLA patients and BTK inhibitor-treated individuals are susceptible to invasive aspergillosis.\",\n      \"evidence\": \"XLA patient and BTKi-treated patient neutrophil assays, neutrophil-specific conditional Btk-KO mice, p40phox/RAC2 activation assays, in vivo aspergillosis model\",\n      \"pmids\": [\"38696257\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BTK directly phosphorylates p40phox or acts through an intermediate kinase not determined\", \"Contribution of BTK to other neutrophil effector functions (e.g., NETosis) not assessed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the full-length structure of activated BTK at a membrane, the complete catalogue of direct BTK substrates in non-B-cell lineages, and the molecular mechanism by which catalytically active BTK restrains PI3Kδ-AKT signaling.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No activated full-length BTK structure available\", \"Direct substrates in NK cells, neutrophils, and microglia remain unidentified\", \"Mechanism of BTK-mediated PI3K-AKT suppression molecularly undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 2, 7, 9, 16, 19]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [9, 10]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1, 9]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [3, 4, 5, 13, 14]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 9, 10, 12, 15, 18]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [6, 7]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [9, 10, 12, 16]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"BLNK\",\n      \"SYK\",\n      \"LYN\",\n      \"PLCG2\",\n      \"HCK\",\n      \"VAV1\",\n      \"AKT1\",\n      \"CLEC7A\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"BTK is a cytoplasmic Tec-family tyrosine kinase that serves as a central signaling hub in B cell development, innate immunity, and inflammatory responses across multiple hematopoietic lineages. BTK is activated downstream of the B cell receptor (BCR), Toll-like receptors, Fc receptors, and Dectin-1 through a two-step mechanism: Src-family kinase (Lyn)-mediated transphosphorylation at Y551 in the activation loop—scaffolded by the adaptor BLNK—followed by autophosphorylation at Y223 in the SH3 domain, with membrane recruitment via PH domain binding to PIP3 or IP6-induced PH-TH dimerization required for activation [PMID:8629002, PMID:8630736, PMID:11226282, PMID:25699547]. Activated BTK phosphorylates PLCγ2, BCAP, the TLR adaptor Mal, and MARCKS to regulate calcium flux, NF-κB signaling, PI3K-Akt activation, and NLRP3 inflammasome assembly, thereby controlling B cell maturation, macrophage polarization, NK cell cytotoxicity, microglial Fc receptor responses, and neutrophil oxidative burst during antifungal defense [PMID:11163197, PMID:16415872, PMID:26059659, PMID:22589540, PMID:34145876, PMID:38696257]. Loss-of-function mutations in BTK cause X-linked agammaglobulinemia (XLA), while drug-resistant kinase-dead BTK mutants retain oncogenic scaffold functions by recruiting alternative kinases such as HCK, a vulnerability overcome by PROTAC-mediated BTK degradation [PMID:8380905, PMID:35639855, PMID:38301010].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Identification of BTK as the gene mutated in X-linked agammaglobulinemia established that a cytoplasmic tyrosine kinase is essential for human B cell development, framing the central biological question of how it transduces receptor signals.\",\n      \"evidence\": \"Positional cloning and mutation analysis in XLA families\",\n      \"pmids\": [\"8380905\", \"8425221\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Substrates and downstream signaling pathways unknown\", \"Activation mechanism uncharacterized\", \"Expression in non-B lineages not yet established\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Demonstration that the BTK PH domain binds Gβγ subunits and PKC isoforms, together with broad hematopoietic expression profiling, revealed BTK as a multi-input signaling node extending beyond the BCR.\",\n      \"evidence\": \"GST-fusion pulldowns, co-immunoprecipitation, in vitro kinase assays, mutagenesis of PH domain tryptophan, Northern/Western blotting across cell lineages\",\n      \"pmids\": [\"7522330\", \"7972043\", \"8283037\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"PH domain lipid-binding specificity not yet resolved\", \"Physiological relevance of G-protein coupling in B cells unclear\", \"PKC phosphorylation sites on BTK not mapped\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Genetic ablation of BTK PH or kinase domains in mice recapitulated the Xid phenotype—reduced B cells, B1 cell loss, IgM/IgG3 deficiency—providing definitive genetic proof that BTK kinase activity and membrane recruitment are both required for B lymphocyte development.\",\n      \"evidence\": \"Targeted gene disruption in ES cells with RAG2-deficient blastocyst complementation and immunological assays\",\n      \"pmids\": [\"7552994\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific signaling events downstream of BTK in developing B cells undefined\", \"Role of BTK in non-B hematopoietic cells not yet tested in vivo\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Mapping the two-step activation mechanism—Y551 transphosphorylation by Src-family kinases followed by Y223 autophosphorylation in the SH3 domain—resolved how BTK is switched on and revealed that Y223 phosphorylation serves a negative regulatory role by modulating SH3-mediated interactions.\",\n      \"evidence\": \"In vitro kinase assays, phosphopeptide mapping, site-directed mutagenesis (Y551, Y223F), BCR crosslinking, fibroblast transformation assays\",\n      \"pmids\": [\"8629002\", \"8630736\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the scaffold bridging Src-family kinases to BTK unknown\", \"Structural basis of autoinhibition unresolved\", \"In vivo significance of Y223 phosphorylation not tested\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Discovery that BTK (together with Syk) phosphorylates the adaptor BCAP to recruit PI3K and generate PIP3 placed BTK upstream of the PI3K-Akt axis within the BCR signaling cascade, and identification of BLNK as the scaffold enabling Syk-dependent BTK activation resolved how BTK is activated in a receptor-proximal complex.\",\n      \"evidence\": \"BCAP and BLNK gene disruption in DT40 cells, PIP3 measurement, Akt phosphorylation, co-immunoprecipitation, SH2 domain interaction analysis\",\n      \"pmids\": [\"11163197\", \"11226282\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full spectrum of BTK substrates unknown\", \"Quantitative contribution of BTK versus Syk to BCAP phosphorylation not determined\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Demonstration that BTK directly binds TIR domains of multiple TLRs and the adaptors MyD88, Mal, and IRAK-1, and is required for TLR4-mediated NF-κB activation, established BTK as an innate immune signaling kinase beyond its BCR role.\",\n      \"evidence\": \"Co-immunoprecipitation, dominant-negative BTK, NF-κB reporter assays, kinase activity assays, pharmacological BTK inhibition\",\n      \"pmids\": [\"12724322\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of BTK-TIR interaction unknown\", \"Role of BTK in TLR signaling in primary innate immune cells not fully dissected\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identification of Mal as a direct BTK substrate whose phosphorylation triggers SOCS-1-mediated ubiquitination and degradation revealed a negative-feedback loop limiting TLR2/TLR4 signaling, showing BTK can both activate and terminate innate immune pathways.\",\n      \"evidence\": \"Phosphorylation assays, ubiquitination assays, SOCS-1 genetic manipulation, NF-κB reporter assays\",\n      \"pmids\": [\"16415872\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Sites of BTK-mediated Mal phosphorylation not fully mapped\", \"Whether this feedback operates equivalently across all TLR-expressing cell types unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Establishing that BTK is required for TLR3-driven NK cell activation extended BTK's functional domain beyond B cells and macrophages into NK cell innate immunity.\",\n      \"evidence\": \"Btk knockout mice, adoptive transfer, in vivo BTK inhibitor, XLA patient NK cell assays\",\n      \"pmids\": [\"22589540\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct BTK substrates in NK cells not identified\", \"Whether BTK regulates other NK receptor pathways unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Recruitment of BTK to Dectin-1-dependent phagocytic cups in macrophages, where it colocalizes with PIP3 and drives DAG synthesis for PKCε recruitment, established BTK as an effector of antifungal phagocytic immunity.\",\n      \"evidence\": \"Live imaging, co-immunoprecipitation, BTK inhibitor, BTK-deficient macrophages, in vivo Candida infection model\",\n      \"pmids\": [\"23825946\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct substrates at the phagocytic cup not identified\", \"Relative contribution of BTK versus Syk to Dectin-1 signaling unclear\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Discovery that ibrutinib resistance arises from the BTK C481S gatekeeper mutation or gain-of-function PLCγ2 mutations defined the first clinical resistance mechanisms and highlighted the pharmacological vulnerability of the covalent bond to Cys481.\",\n      \"evidence\": \"Whole-exome sequencing of CLL patients at baseline and relapse, functional analysis of C481S\",\n      \"pmids\": [\"24869598\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether kinase-dead Cys481 mutants retain signaling function not yet explored\", \"Resistance mechanisms beyond Cys481 and PLCγ2 undefined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Structural resolution of BTK autoinhibition—a compact conformation stabilized by PH-TH, SH2, and SH3 modules, relieved by IP6-induced PH-TH dimerization—provided the first atomic-level explanation of how membrane recruitment triggers kinase activation, complementing the biochemical activation model.\",\n      \"evidence\": \"X-ray crystallography, IP6 binding experiments, mutagenesis of PH-TH dimerization interface, in vitro kinase assays\",\n      \"pmids\": [\"25699547\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length BTK structure not solved\", \"Dynamics of PH-TH dimerization on native membranes not captured\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstration that BTK physically interacts with ASC and NLRP3 and is required for inflammasome activation, caspase-1 cleavage, and IL-1β maturation broadened BTK's role to sterile inflammation and ischemic brain injury.\",\n      \"evidence\": \"Co-immunoprecipitation of BTK-ASC and BTK-NLRP3, Btk-deficient mice, ibrutinib treatment, mouse brain ischemia model\",\n      \"pmids\": [\"26059659\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BTK phosphorylates NLRP3 or ASC directly is unknown\", \"Mechanism of BTK-NLRP3 interaction not structurally resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Systematic mutagenesis revealing that co-occurring gatekeeper (T474) and kinase-domain mutations produce a 10–15-fold gain in kinase activity with de novo transforming potential uncovered a mechanism by which autoinhibition can be catastrophically disrupted.\",\n      \"evidence\": \"Systematic BTK mutagenesis screen, in vitro transformation assays, in vivo xenografts, computational structural analysis\",\n      \"pmids\": [\"31217352\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Frequency of these compound mutations in patients not determined\", \"Structural basis of synergistic autoinhibition loss not fully resolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Discovery that kinase-dead BTK C481F/C481Y mutants sustain BCR signaling by recruiting HCK via Y551-SH2 interactions revealed a kinase-independent scaffold function, fundamentally redefining the drug target from enzymatic activity to protein presence.\",\n      \"evidence\": \"In vitro kinase assays confirming kinase-dead status, co-immunoprecipitation of BTK-HCK, phosphorylation and clonogenic assays\",\n      \"pmids\": [\"35639855\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full repertoire of kinases recruited by scaffold BTK unknown\", \"Whether scaffold function operates in non-B cell contexts unexplored\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"PROTAC-mediated degradation of mutant BTK proteoforms (NX-2127) achieved >80% BTK depletion in CLL patients and blocked BCR signaling irrespective of kinase activity, providing clinical proof-of-concept that degradation overcomes scaffold-mediated resistance; separately, neutrophil-specific Btk deletion established BTK as essential for NADPH oxidase-dependent antifungal defense via p40phox and RAC2 activation.\",\n      \"evidence\": \"PROTAC degradation assays and clinical trial data; conditional Btk KO mice, human XLA neutrophils, in vivo aspergillosis model\",\n      \"pmids\": [\"38301010\", \"38696257\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Long-term clinical efficacy of BTK degraders unknown\", \"Mechanism by which BTK activates p40phox and RAC2 not fully dissected\", \"Impact of BTK degradation on NLRP3 inflammasome versus inhibition not compared\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A full-length BTK structure in its native membrane context, the complete substrate repertoire in each innate immune cell type, and the structural basis of BTK's scaffold interactions with HCK and NLRP3 remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No full-length BTK structure on membranes\", \"Complete substrate inventory in macrophages, neutrophils, and microglia lacking\", \"Structural mechanism of kinase-independent scaffold signaling unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [5, 6, 8, 12, 13, 20, 25, 26]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [26, 28]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [2, 19]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 5, 10]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [5, 15, 19]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 4, 11, 12, 14, 15, 17, 18, 23, 29]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [5, 6, 8, 9, 11, 16, 21, 26]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [16, 21, 24, 26, 28]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [7, 20]}\n    ],\n    \"complexes\": [\n      \"NLRP3 inflammasome\"\n    ],\n    \"partners\": [\n      \"PLCG2\",\n      \"BLNK\",\n      \"HCK\",\n      \"LYN\",\n      \"NLRP3\",\n      \"PYCARD\",\n      \"MYD88\",\n      \"TIRAP\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}